



Yunkang Group Limited

(Incorporated in the Cayman Islands with limited liability)

Stock Code : 2325



2025

**ENVIRONMENTAL, SOCIAL AND
GOVERNANCE REPORT**

CONTENT

1	About this Report	2	6	Advance Progress With Partners With Excellence In Quality And Efficiency	40
	Reporting Scope	2		Dual-Driven Operations Of Quality And Efficiency	40
	Definition Of Terms	2		Enhancing Service Quality	47
	Data Source	2		Improving Innovation Mechanisms	53
	Report Preparation Standard	2		Deepening Ecological Synergy	55
	Reporting Principles	3	Environment and Climate		
	Report Access And Contact	3	7	Pursue Sustainable Development Through Low-Carbon Practices	61
2	Message from the Chairman	4		Promoting Green Operations	61
3	About Yunkang Group	6		Addressing Climate Change	70
	Introduction To Yunkang	6	Social and Inclusion		
	Performance Of The Year	8	8	Share Prosperity For All Through People-Centric Development	80
	Honors And Recognitions	9		Protecting Employee Rights	80
	Sustainability Highlights	10		Caring For Employee Health	85
				Empowering Employee Growth	87
Governance and Innovation			9	Care For The Community With Benevolence	93
4	Maintain Leadership In Health Sector Through Intelligence-Driven Innovation	12		Safeguarding Public Health	93
	Model Innovation	12		Empowering People's Livelihood Through Public Welfare	97
	Technological/Product Innovation	14	10	APPENDIX 1: ESG KPIS	99
	Digital and Intelligent Innovation	16		Environmental KPIS	99
	Industry-university-research Innovation	20		Social KPIS	101
5	Seek Long-Term Success Building Upon Integrity	23	11	APPENDIX 2: Index of ESG Reporting Code of the Stock Exchange	106
	Corporate Governance	23			
	Sustainability Governance	29			

1 ABOUT THIS REPORT

Yunkang Group Limited is pleased to publish its fourth annual Environmental, Social and Governance (“ESG”) Report (the “Report”), which provides a full view of the Company’s ESG-related strategic approach, management measures and performance to address the concerns and expectations of stakeholders on the Company and enhance their understanding of and trust in the sustainability strategies and actions of the Company.

REPORTING SCOPE

The Report is an annual report. Where not otherwise stated, the content in the Report covers a period from January 1, 2025 to December 31, 2025 (“2025”, the “Year” or “Reporting Period”). The Reporting scope of the Report is consistent with that of the 2025 annual report (the “Annual Report”) of the Company. The policies and data provided in the Report cover the Company and its subsidiaries.

DEFINITIONS OF TERMS

To facilitate presentation and reading, unless otherwise specified, “Yunkang Group”, “Yunkang”, the “Company” or the “Group” in the Report refers to Yunkang Group Limited. The term “co-laboratories” in the Report also refers to as “on-site diagnostic centers” and “co-construction services” as “diagnostic testing services for medical institution alliances”.

DATA SOURCE

The information and data used in the Report are mainly derived from Yunkang’s official documents and reports, internal statistical data and public information. Where not otherwise stated, monetary amounts referred to in the Report are measured in Renminbi (“RMB”). The Company undertakes that the Report contains no false records or misleading statements, and is responsible for the authenticity, accuracy and completeness of its content.

REPORT PREPARATION STANDARD

The Report complies with mandatory disclosure requirements and the “comply or explain” provisions in the Environmental, Social and Governance Reporting Guide (the “*ESG Reporting Code*”) set out in Appendix C2 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “*Hong Kong Listing Rules*”) issued by The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”). An index of content of “comply or explain” provisions is provided in Appendix 2 of the Report for quick reference.

REPORTING PRINCIPLES

Reporting Principles	Definitions of Reporting Principles in the <i>ESG Reporting Code</i>	Yunkang's Response
Materiality	The threshold at which ESG issues determined by the board are sufficiently important to investors and other stakeholders that they should be reported.	Through the materiality assessment review, the Group prioritized the 2025 list of material issues, identified the material issues relevant to the Group, and made corresponding disclosures in the Report. The procedures for the materiality assessment review included identifying the Group's key stakeholders, updating the database of potential ESG issues, and prioritizing the list of material issues. For details regarding the materiality assessment review, please refer to the "Materiality Assessment" section of the Report.
Quantitative	KPIs in respect of historical data need to be measurable. The issuer should set targets for mitigating individual impacts (which may be quantified figures or directional, forward-looking statements). In this way, the effectiveness of the ESG policies and management systems can be evaluated and verified. Quantitative data should be accompanied by explanations elaborating on their purposes and impacts, and comparative data should be provided where appropriate.	To comprehensively evaluate the Group's ESG performance during the Reporting Period, the Group has disclosed the applicable quantitative KPIs set out in the <i>ESG Reporting Code</i> , and specified the standards, methodologies, assumptions, and calculation references adopted for such quantitative KPIs, including the sources of the main conversion factors.
Consistency	The issuer should use consistent methodologies to allow for meaningful comparisons of ESG data over time.	Where practicable, the Report uses the consistent statistical and collection methodology as used in the previous Reporting Period to allow stakeholders to make meaningful comparisons of the performances for the Reporting Period. If there is any change in the methodology, such change will be presented and elaborated in the corresponding section.
Balance	ESG reports should present the issuer's performance in an unbiased manner, avoiding selections, omissions, or presentation formats that may inappropriately influence the decision-making or judgment of the readers of the Report.	The Report provides an unbiased picture of the Group's performance for the Reporting Period. The Report avoids selections, omissions, or presentation formats that may inappropriately influence the readers' decision-making or judgment.

REPORT ACCESS AND CONTACT

The Report is published in both Chinese and English, respectively and in case of any discrepancies, the Chinese version shall prevail. The electronic version of the Report is available on the HKEXnews website of the Hong Kong Stock Exchange (www.hkexnews.hk) or the Company's official website (www.yunkanghealth.com). If you have any questions or comments about the Report and its content, please contact us through the following contact methods.

Address: No. 6 Lizhishan Road, Science City, Huangpu District, Guangzhou, China

Website: www.yunkanghealth.com

Email: ir@yunkanghealth.com

2 MESSAGE FROM THE CHAIRMAN

2025 is a crucial year for Yunkang Group as it empowers high-quality medical development through digital intelligence and professionalization. At present, the global medical and healthcare industry is accelerating its transition from being “disease-centered” to “people’s health-centered”. Technological innovation, digital transformation and intelligent upgrading, collaborative governance, and sustainable development are profoundly reconstructing the industry’s value and service ecology. Facing the opportunities of the times and industry transformations, Yunkang takes **professionalization as the foundation, standardization as the core, digital intelligence as the means, and collaboration as the goal**. With in-depth medical institution alliances services as the cornerstone, innovation integrating industry, academia, research, and healthcare as the engine, and lean operations coupled with ESG concepts as the support, we make every effort to boost the construction of a “Healthy China”.

Looking back at 2025, we strengthened our medical services to lay a solid foundation for development. The Group continued to advance the “one horizontal, one vertical” strategy. Horizontally, we expanded multi-mode cooperation, implemented benchmark projects such as regional medical testing centers, and served hundreds of medical institution alliances clients nationwide. Vertically, we deepened hospital-enterprise collaboration and joint medical testing innovation, joined hands with top-tier universities and medical institutions to build innovation platforms, developed dozens of cutting-edge projects, jointly released authoritative industry expert consensus, and promoted the efficient transformation of scientific research achievements. At the same time, we built an operational system leveraged on the mega-delivery center, expanded our service radius, and achieved a dual improvement in cost reduction, efficiency enhancement, and service capabilities.

We embraced the digital and intelligent transformation to lead the upgrading of diagnostics. In 2025, Yunkang’s digital and intelligent construction entered a new stage by deploying the agent “Xiao Yun”, jointly releasing the medical large model “Zhi Yun”, and collaborating with data exchanges to launch medical testing data products, thereby driving diagnostic precision and service efficiency with AI and big data, and continuously embarking on a new journey of digital and intelligent medical diagnostics.

We adhered to compliance and integrity to consolidate the baseline of governance. The Group continuously improved its corporate governance and compliance system, strengthened risk control and fostered a culture of integrity. Its medical laboratories passed authoritative compliance and integrity management system certifications, building a solid foundation for honest operations through institutionalization and standardization, thereby safeguarding the sustainable and high-quality development of the enterprise.

We fulfilled our green mission and advanced low-carbon operations. Actively responding to the national “dual carbon” strategy, we improved the greenhouse gas accounting system, completed the data collection of Scope 3 emissions, comprehensively implemented green logistics, energy-saving renovations, and paperless management, and increased the application proportion of new energy transport vehicles, building a “Low-Carbon Yunkang” with pragmatic actions to safeguard ecological sustainability.

We actively fulfilled social responsibilities to protect the health of all people. Always taking benefiting the people’s health as our original aspiration, we went deep into communities to conduct charitable clinical diagnostic activities, free health check-ups, and popular science education, serving tens of thousands of person-times. Focusing on the health security of key populations, we delivered warmth through professional testing and medical services, making high-quality health resources accessible and inclusive.

We cherished the value of talent and activated the driving force for development. Insisting on talent as the core asset, we improved the dual-track career progression and training system, iterated the “Fu Yun” learning platform, cultivated interdisciplinary medical talents, and built a warm, vibrant, and growth-oriented talent ecology, injecting endless driving force into the Group’s long-term development.

Looking ahead, Yunkang will continue to uphold its core values of integrity, honesty and client-oriented approach, deepen the collaborative innovation of medical institution alliances, strengthen the deep integration of digital and intelligent technologies with medical services, and continuously elevate the level of ESG governance. We sincerely thank all employees, customers, partners, and investors for their trust and companionship. In the future, Yunkang will guard its original aspiration with professionalism, create value with technology, and shoulder its mission with responsibility. Striving for steady and sustained progress, we will make greater contributions to a “Healthy China” and the health and well-being of all people!

Zhang Yong


Chairman and Chief Executive Officer of Yunkang Group

April 2026

3 ABOUT YUNKANG GROUP

3.1 INTRODUCTION TO YUNKANG

Yunkang Group is a leading medical operation service provider in China. Having deeply cultivated the medical service field for over two decades, it has always been committed to meeting the health needs of its customers. Through professional medical diagnosis services, robust standardization capabilities, and innovative business models, it provides professional, accurate, efficient, and convenient medical and healthcare service solutions for medical institutions at all levels.



As one of the first medical operation service institutions in China to obtain dual accreditations from ISO 15189 and CAP, Yunkang leverages its professional technology and standardized services to promote the development of China's medical and healthcare industry. Yunkang has built an integrated innovation system of "industry, academia, research, and healthcare", possessing the strength in scientific research transformation and clinical application. Its services cover multiple clinical fields such as infections, hematology, reproductive genetics, immunology, cardiovascular diseases, and oncology, providing clinical testing and pathological diagnosis services relying on cutting-edge technology platforms and scientific research innovation.

The Group's core businesses encompass professional medical testing services, medical institution alliances construction and operation services, and public health services. It possesses outstanding technical strength and industry advantages in cutting-edge technology fields such as molecular diagnostics, gene sequencing, and digital pathology, precisely matching clinical and public health needs.

At the same time, relying on a nationwide medical testing and service network, Yunkang leverages its standardized, professional, and intelligent diagnostic capabilities to help elevate the level of public health services and promote the high-quality development of China's healthcare industry.

3.2 PERFORMANCE OF THE YEAR

Business

Total assets
RMB2.735 billion

Total revenue for 2025
RMB601 million

Operation

Serving **nearly 450** leading hospitals
jointly constructed by the medical
institution alliances

Serving **over 1,500**
medical institution alliance clients

Governance

No litigation
on corruption for the full year

Proportion of independent Directors
more than 40%

Proportion of female Directors
14.3%

Employees

Proportion of females in the management
35.42%

Proportion of female employees
57.24%

Cumulative learning on the “Fu Yun”
learning platform
24,400 person-times

Total training hours of employees
11,809 hours

Number of work-related fatalities for the full year
0 person

Environment

Energy consumption intensity
8.00
thousand kWh/million RMB

Carbon emission intensity
15.99
tCO₂e/million RMB

Percentage of new energy vehicles of
nationwide cold chain logistics vehicles
approximately
70%

Social

Total number of launching community
charitable clinical diagnostic activities
245 times

Total number of complimentary
medical examination
over 25,636 person-times

Charitable clinical diagnostic
activities served over
14,770 person-times

3.3 HONORS AND RECOGNITIONS

Major Awards in 2025

The S&P Global Corporate Sustainability Assessment (CSA) score increased from 43 to 48 in 2025*
Listed in the *S&P Global Sustainability Yearbook (China Edition)* for two consecutive years



High-tech Enterprise – Outstanding Achievement Award (for 15 consecutive years)



Wind ESG Rating upgraded to
AA grade



Won the TVB ESG Social Innovation and Technology Award



Outstanding performance in External Quality
Assessment (EQA) certifications for laboratories



Recognition of data products



* ESG Rating Disclaimer: The Report contains references to the S&P Global ESG Score, which shall not constitute any recognition or endorsement of the Group by S&P Global. All rating scores presented herein are based on publicly available information and relevant scores for the Year.

3.4 SUSTAINABILITY HIGHLIGHTS

Governance and Innovation

- Closely aligned with policy guidelines, the Group adopts the core strategy of “In-depth Services Lean Operations” and steadily executes the **“one horizontal, one vertical” strategy**. We replicate our **lean operations system** and provide smart digital solutions and regional diagnosis centers to nearly 450 medical institution alliances, solidifying our core healthcare service foundation. We **deepen joint innovation in medical testing** by partnering with universities and leading hospitals to accelerate research commercialization and product upgrading. Leveraging digital intelligence and industry-university collaboration, we elevate overall business performance and continuously drive innovation across the healthcare sector
- Comprehensively upgraded **three major digital and intelligent systems, namely “Zhi Yun”, “Xin Yun”, and “Teng Yun”**, promoting the intelligentization of medical data, the visualization of clinical operations, and the digitalization of operation and management
- Built the **AI Pathology Platform 2.0 and an embedded AI integrated chromosome analysis system**, realizing the full-process digitalization and intelligentization of pathology and chromosome testing
- Conducted a **materiality assessment review** to ensure that relevant issues continuously align with Yunkang’s development strategy and industry development trends
- Improved the internal control and risk management system, strengthened compliance and anti-corruption governance mechanisms, implemented an integrity culture and a whistle-blowing and monitoring system, and comprehensively **elevated the level of corporate risk prevention, control, and compliant operations**

Environment and Climate

- Continuously tracked and reviewed the execution of environmental targets, and the **targets for greenhouse gas (GHG) emissions, waste generation, and energy use efficiency have all been successfully achieved**
- Continuously advanced **low-carbon green logistics**, comprehensively enhanced transportation efficiency and environmental protection efficacy through new energy transportation, paperless operations, and intelligent monitoring, achieving energy conservation, carbon and emission reduction, and green operations
- **Reviewed climate-related risks and opportunities, conducted a qualitative analysis** of the **potential financial impacts** of climate-related risks and opportunities, and examined and reviewed the **management measures/action plans** for each significant climate risk and opportunity
- **Collected and accounted data of relevant categories of GHG Scope 3**, actively responding to the relevant requirements of the *ESG Reporting Code*

Social and Inclusion

- Built a talent development framework featuring **“dual-track career progression” and “four major training systems”**, driving professional training and certifications for the **marketing line, laboratory technology line, functional line, and digital transformation line**, thereby strengthening employees’ professional competence and career competitiveness
- Actively promoted the **“National Health Protection Action”**, utilized professional medical resources to go deep into communities to hold health knowledge lectures, charitable clinical diagnostic activities, and complimentary physical examinations, cared for key groups such as children and the elderly, and comprehensively elevated public health awareness and disease prevention capabilities
- Deeply cultivated the field of **“community charity and public welfare”**, innovated the **“idle land + public welfare”** service model, combined projects such as agricultural assistance for poverty alleviation and educational donations, established a new replicable and promotable benchmark for livelihood services, and conveyed social warmth and positive public impact with tangible actions

GOVERNANCE AND INNOVATION

4 Maintain Leadership In Health Sector Through Intelligence
-Driven Innovation

5 Seek Long-Term Success Building Upon Integrity

6 Advance Progress With Partners With Excellence In
Quality And Efficiency



4 MAINTAIN LEADERSHIP IN HEALTH SECTOR THROUGH INTELLIGENCE-DRIVEN INNOVATION

Actively responding to policy directions, Yunkang takes “In-depth Services, Lean Operations” as its core strategy, focusing on precision diagnosis and digital medicine. The Group continuously drives technological innovation and model upgrading, and collaborates with industry chain partners to enhance medical technology and service capabilities, thereby meeting the diversified and high-quality needs of clinical institutions.

**In-depth
Services
Lean
Operations**

4.1 MODEL INNOVATION : CONSTRUCTING A NEW SYSTEM OF COMPREHENSIVE MEDICAL SERVICES

2025 was a crucial year for deepening medical reform and accelerating the construction of a “Healthy China”. In the face of population aging, growing demand for chronic disease management, and the digital medical transformation, the state is promoting the channeling of high-quality medical resources to lower levels, improving the hierarchical diagnosis and treatment and public health systems, and driving the transition of medical services from being “disease-centered” to “people’s health-centered”. Yunkang takes model innovation as its starting point, deepens service models such as the medical testing joint innovation platform, regional testing/pathology centres, and county-level medical and health communities, promotes the balanced development of regional medical resources, and allows more people to benefit from high-quality medical services.

Achievements in the Construction of the Medical Service System

To date, the Group has provided diversified services to nearly 450 clients of medical institution alliances, covering artificial intelligence (AI) + medical institution alliances digital and intelligent solutions, overall medical laboratory cooperation, regional and pathology center construction, precision medicine center and specialist alliance development, further consolidating Yunkang to continue to provide solid support for the high-quality development of medical institution alliances.

- (1) Yunkang pioneered the model of joint innovation platform for diagnostic testing services, establishing in-depth partnerships with dozens of leading medical institutions across the country to strengthen clinical diagnostic support and the translation of research findings into practical applications; At the same time, Yunkang has established long-term strategic partnerships with numerous renowned universities, including Fudan University, The Hong Kong Polytechnic University and Jinan University, as well as authoritative medical institutions such as Guangdong Provincial People’s Hospital, the Guangxi Hospital of the First Affiliated Hospital of Sun Yat-sen University, Xiangya Hospital of Central South University and the First Affiliated Hospital of Jinan University. Working collaboratively in areas such as research translation, product innovation, data application and the development of specialist ecosystems, Yunkang is continuously enhancing clinical precision diagnosis and treatment capabilities.

Precision Medication Field

Collaborated with the First Affiliated Hospital of Jinan University, leveraging pharmacogenetic testing achievements to assist in precision medication for depression treatment

Launch Major Scientific Research Projects

Collaborated with the Guangxi Hospital of the First Affiliated Hospital of Sun Yat-sen University to carry out research on innovative biomarkers and disease course monitoring for allergic rhinitis, promoting the deep integration of specialist scientific research innovation and clinical application

- (2) Jointly build a regional testing/pathology center, construct a remote pathology collaboration network, and improve the region’s diagnostic standardization capabilities. In July of the same year, the “Regional Medical Testing Center” co-built by Yunkang and Guangzhou Baiyunshan Hospital was officially put into operation. The center focuses on resource co-building and technical standardization, promotes the intensification and digital management of testing capabilities, and provides demonstration and support for the implementation of hierarchical diagnosis and treatment, the collaboration between public and social healthcare, and the sustainable development of the regional medical system.



- (3) Deeply empowering county-level medical community. By carrying out close-knit medical alliance cooperation with county general hospitals, Yunkang integrates county-level medical resources and enhances testing service efficiency and diagnosis and treatment capabilities. At the Yilong County General Hospital in Sichuan Province, Yunkang assisted in constructing a regional medical logistics network covering five major hospital districts and 34 townships, improving sample circulation and medical collaboration capabilities. Meanwhile, relying on Yunkang’s professional services and high-quality resources, the Longmen County Pathology Diagnosis Center in Guangdong Province has benefited over 300,000 residents, promoting the high-quality development of county-level healthcare.

4.2 TECHNOLOGICAL/PRODUCT INNOVATION: DEEPENING PRECISION DIAGNOSIS AND TREATMENT ACROSS ALL SCENARIOS

With clinical rigid demands, disease areas, and patient benefits at its core, Yunkang continues to deeply cultivate the research, development, and clinical transformation of precision diagnosis technologies, and comprehensively enhances the precision, accessibility, and standardization of disease diagnosis, providing full-scenario and high-quality diagnostic support for fields such as oncology, infectious diseases, genetics, and women’s and children’s health.

- (1) Relying on the mature medical testing joint innovation cooperation model, Yunkang has jointly developed dozens of innovative testing items with dozens of medical institutions nationwide, covering various infectious syndromes in multiple fields, including respiratory tract infections, central nervous system infections, urinary tract infections, reproductive tract infections, and tuberculosis infections, as well as pharmacogenetic testing for depression and anxiety treatments, comprehensively supporting early disease screening, precise typing, and individualized diagnosis and treatment.

Assisting in the Precision Diagnosis of Breast Cancer	Assisting in the Precision Pathological Diagnosis of Cervical Cancer	Assisting in the Precision Diagnosis of Pediatric Infectious Diseases
<p>Yunkang focuses on the prevention and control of female tumors, leveraging next-generation sequencing (NGS) technology to build a multi-gene testing system for breast cancer, and has developed a series of products for breast cancer risk assessment and typing, achieving precision diagnosis and individualized treatment support from early screening to medication guidance.</p>	<p>Centering on the integrated needs of cervical cancer screening, diagnosis, and treatment, Yunkang has established a human papillomavirus (HPV) variation detection and cervical pathology typing platform, driving the transition of cervical cancer prevention and control from routine screening to hierarchical diagnosis, and enhancing diagnostic accuracy and clinical application value.</p>	<p>Yunkang launched the targeted sequencing service of common pediatric pathogens, which can simultaneously detect 167 infection-related pediatric pathogens. Relying on bioinformatics analysis, the pathogenic pathogens in samples such as respiratory and anal swabs can be accurately identified, and the typing and detection of adenovirus and enterovirus can be realized, which can effectively assist clinical diagnosis and prognosis assessment, and provide support for personalized and precise treatment for pediatric infectious diseases.</p>

- (2) Yunkang actively advances academic research and the construction of industry standardization. During the Reporting Period, Yunkang co-released the Expert Consensus on the Standardized Application of Targeted Next-Generation Sequencing in the Diagnosis and Treatment of Infectious Diseases (2025) with Guangdong Provincial People's Hospital and other institutions, promoting the standardized application of targeted next-generation sequencing (tNGS) technology in clinical diagnosis and treatment. The Company also co-published tNGS research results on urinary system infections with the First Affiliated Hospital of Guangzhou Medical University in an authoritative international journal, further enhancing its industry influence.



At the same time, Yunkang carried out multiple scientific research projects with several hospitals in disease areas such as ophthalmology, dermatology, and parasitology, promoting the standardization and clinical practical application of emerging testing technologies.

4.3 DIGITAL AND INTELLIGENT INNOVATION: BUILDING A NEW AI + INTELLIGENCE HEALTHCARE ECOSYSTEM

Yunkang integrates cutting-edge technologies such as AI, cloud computing, big data, and 5G to promote the digital and intelligent upgrade of the entire process of medical services and operations management, thereby reducing costs, increasing efficiency, and improving service quality.

(1) Construct Yunkang’s digital and intelligent management platform, covering the whole process of laboratory operation, customer management and operation analysis, to create a one-stop intelligent diagnosis service solution.

“Cloud” System Innovation


With the 10 digital “cloud” systems as the core engine, Yunkang comprehensively advances its digital and intelligent transformation. The systems cover businesses such as laboratory operations, sales, human resources, training, and customer service, creating a one-stop smart diagnosis solution from “sample collection” to “report delivery”. At the same time, it uses digital technology to optimize processes, enhance quality and efficiency, and drive lean management, while also outputting the digital operation system to help clients achieve efficient collaboration and precise decision-making, promoting the upgrading of the medical service value chain.



During the Reporting Period, Yunkang continuously deepened the innovation of the three core systems, “Zhi Yun”, “Xin Yun”, and “Teng Yun”, driving medical services and corporate management towards a comprehensive digital and intelligent upgrade.

• “Xin Yun” System

During the Year, Yunkang launched the upgraded “Xin Yun” system, which integrated AI technology to achieve intelligent report generation, to improve service efficiency and quality, reduce communication costs, strengthen customer stickiness and operational efficacy, and drive the intelligent and precise development of service management. The system introduced facial recognition technology for clinicians, opened account management permissions for medical technology departments, supported clients in initiating demands online, and provided foundational service capabilities such as sample panoramic tracking and an order-report middle platform, building an efficient and smart integrated medical operation platform.



• “Teng Yun” System

The “Teng Yun” system integrates external customer management and internal business operation functions, covering core processes such as CRM, contracts, archives, and bidding. After more than two years of continuous improvement, the system has achieved efficient connection and unified management among various processes. In 2025, Yunkang further extended its management focus to the operational end. Through the “Teng Yun” system, it strengthened the unified tracking and analysis of key indicators such as client business, profits, and payment collections, driving the formation of a management mechanism oriented towards operational efficiency and cash flow, and enhancing the overall operational quality of the Company.

(2) Yunkang released the large-scale medical model of “Zhi Yun”, implemented core functions such as generating medical records, quality control and convenient medical treatment, launched the “AI + Digital and Intelligent Medical Institution Alliances/Medical Community” solution and carried out pilot application.

• “Zhi Yun” System


In May 2025, Yunkang co-released its first medical large model, “Zhi Yun”, marking a significant breakthrough for the Company in the field of AI and medical digital-intelligent integration. Yunkang combined the Zhi Yun large model with the medical institution alliances co-building model, launched the “AI + Digital and Intelligent Medical Institution Alliances/Medical Community” solution, and carried out pilot applications among cooperative medical institution alliances clients relying on core modules of the Zhi Yun system such as “outpatient medical record generation”, “specialist medical record generation”, “outpatient and medical record quality control”, and “convenient medical treatment”.



- (3) In 2025, Yunkang focused on innovative scenarios of “AI + Medical Diagnosis”, advanced platform construction and algorithm optimization surrounding remote pathology consultation, chromosome analysis, and pathological diagnosis, achieving the automation of testing processes, high precision of diagnosis results, and high efficiency of service collaboration.


• **Upgrading of the Remote Pathology Platform**

Yunkang continuously advanced the “Medical + Digital” construction, built a Remote Pathology Consultation Platform, and integrated domestic and international pathology experts and medical resources. The platform strictly follows the CAP, CLSI, and domestic pathology standard specifications, driving remote diagnosis, quality control, and academic cooperation. In 2025, the platform completed its integration with cervical AI cytology software, cumulatively completing 20,000 cases of AI-assisted diagnosis of cervical liquid-based cytology, significantly improving diagnostic efficiency and accuracy. As of the end of the Reporting Period, Yunkang’s Remote Pathology Consultation Platform has covered over 800 medical testing items, assisting more than 200 medical institutions nationwide in enhancing their pathological diagnosis capabilities, and benefiting over 200 million rural patients in remote areas.




• **AI Chromosome Analysis System**

Supported by the national “Digital Economy” project, Yunkang built an embedded AI integrated chromosome analysis system. Relying on algorithm training with millions of samples, it achieved automatic segmentation and abnormality localization, with an identification accuracy of over 99%. The system can process 200 images within six minutes per scan and supports 24-hour continuous operation, advancing Yunkang’s intelligent upgrade in the “AI + Medical Testing” field.



- **AI Pathology Platform**

In 2025, Yunkang upgraded and constructed the AI Pathology Platform 2.0, realizing the full-process digitalization of pathology testing through process optimization and intelligent diagnosis, shortening the testing turnaround time by 6-8 hours and improving per capita efficiency by 100%. The cytopathology AI technology cumulatively completed over 300,000 cases of cervical cell diagnosis, significantly improving diagnostic accuracy and timeliness. The platform's applications covered areas such as gynecology, breast, and gastrointestinal tract, promoting the integrated "AI + Manual" slide reading and 5G remote pathology collaboration, and assisting in the digital and intelligent upgrade of tumor diagnosis and precision medicine.



**Per Capita Work Efficiency
Increased**

100%

**AI-Assisted Diagnosis of Cervical
Cytopathology**

Over **300,000** cases

4.4 INDUSTRY-UNIVERSITY-RESEARCH INNOVATION: ACTIVATING MEDICAL AND HEALTH INNOVATION DRIVERS

Yunkang is committed to deepening the integration of industry and education, medical research collaboration, and industrial cooperation, building a full-chain innovation ecosystem, so as to continuously create new quality productive forces and inject enduring innovative momentum into the medical and healthcare industry, as well as assist the industry in moving towards a higher-quality, more efficient, and sustainable development direction.

- (1) Relying on its nationwide service network and abundant clinical resources, Yunkang actively joins hands with universities, scientific research institutions, and industry chain partners to build an innovative ecology integrating “industry, academia, research and medicine”, contributing to social health and well-being.



Yunkang Signed a Memorandum of Cooperation with The Hong Kong Polytechnic University

On March 13, 2025, Yunkang and The Hong Kong Polytechnic University signed a memorandum of cooperation in Guangzhou. Relying on the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, the two parties deepened medical research collaboration and the integration of industry and education, aiming to create a “Bay Area Medical Service Model”. The two parties co-built the “Cloud Medical Training Base”, promoted the implementation of the CLSI quality system and international certification standards, and cultivated high-end medical talents with clinical innovation and application capabilities, thereby promoting the high-quality development of the regional medical industry.



Co-building a Medical Testing Practice Base with Guangzhou Nanfang College

Yunkang deepened its school-enterprise cooperation with Guangzhou Nanfang College to co-build a medical testing practice base, driving the training of “dual-qualified” teachers and the cultivation of application-oriented talents. Relying on the Yunkang Health Medical Platform, it conducted standardization and quality management training jointly organized with CLSI, cumulatively training nearly 1,000 students with an employment rate of over 90%, and has become a paradigm of the integration of medical education and industry.



- (2) Yunkang deepened the collaborative development of “medicine, research, and enterprise”, promoting the integrated innovation of clinical scientific research and industrial applications. Relying on its advantages in precision diagnosis and scientific research technology, it built a cooperation system covering scientific research, diagnosis, and regional medical services, facilitating the transformation of achievements and clinical applications, improving diagnosis and treatment efficiency, and assisting in the high-quality development of regional healthcare.



Joining Hands with Guangdong Provincial People’s Hospital to Accelerate Scientific Research Innovation and Achievement Transformation

Yunkang signed a strategic cooperation agreement with Guangdong Provincial People’s Hospital, focusing on the precision diagnosis and treatment of infectious diseases, and promoting the implementation of smart healthcare and innovative testing technologies. The two parties co-built the first LDT standardized incubation model and a “1 + N” medical-testing collaborative network in China, achieving multiple innovative breakthroughs in areas such as respiratory and central nervous system infections, and driving the clinical transformation of scientific research achievements.



Collaborating with the First Affiliated Hospital of Kunming Medical University to Conduct Scientific Research on Precision Diagnosis and Treatment

Yunkang carried out scientific research cooperation with the First Affiliated Hospital of Kunming Medical University. Relying on their respective clinical and technological advantages, the two parties jointly conducted research, development, and achievement transformation surrounding respiratory infectious diseases. The two parties built a localized NGS testing standard system, enhancing the precision diagnosis and clinical scientific research capabilities for respiratory infectious diseases in the Yunnan region.



- (3) Yunkang collaborated with various parties across the industry chain to implement strategic partnerships and professional training, deepen collaboration in early cancer screening and precision diagnosis, and drive comprehensive innovation and advancement of the industry ecosystem.



Yunkang Officially Signed a Strategic Cooperation Agreement with Guangzhou Targene Biotechnology Co., Ltd.

On April 29, 2025, Yunkang signed a strategic cooperation agreement with Guangzhou Targene Biotechnology Co., Ltd. to carry out in-depth collaboration focusing on precision tumor diagnosis and early cancer screening. The two parties focused on resource integration, achievement transformation, network co-building, and health management, advanced the application of cutting-edge technologies such as NGS and methylation testing, and promoted the transformation of testing achievements and the upgrading of clinical diagnosis and treatment.



Jointly Organized the “National Testing Training Camp (First Session)” with Mumianhua Reproduction, Guangdong Medical Association, and Guangzhou Ai’an Clinical Laboratory Center

In September 2025, Yunkang, together with Mumianhua Reproduction and Guangdong Medical Association, held the “National Testing Training Camp (First Session)”, focusing on AI and reproductive andrology testing technologies to promote professional capacity building and clinical integration. The event gathered authoritative experts to conduct case analysis and practical teaching, strengthened the skills and quality management of technical personnel, improved testing accuracy and traceability, and promoted the enhancement of medical service quality.



In 2025, Yunkang Group actively participated in multiple academic activities, covering fields such as precision medicine, infectious diseases, clinical testing, psychological assessment, and women’s and children’s health. By strengthening academic exchanges and technical cooperation, it promoted the accelerated transformation of scientific research achievements and enhanced the quality of medical services and the level of industry innovation.

Participated in and co-organized academic conferences

117 sessions

Participated in and co-organized national first-class conferences

6 sessions


5 SEEK LONG-TERM SUCCESS BUILDING UPON INTEGRITY

A sound governance structure is an important cornerstone for the continuous and steady development of an enterprise. Yunkang adheres to the governance principles of integrity, transparency, accountability, and independence, continuously improves its management system, and strengthens its internal supervision and risk control mechanisms. Taking compliant operations as the fundamental principle and being guided by high-standard business ethics, the Group is committed to safeguarding shareholders' rights and interests, creating long-term and sustainable value, continuously cultivating an honest and upright corporate culture, and shaping a trustworthy brand image.

5.1 CORPORATE GOVERNANCE

5.1.1 Governance Structure

Yunkang strictly complies with the Company Law of the People's Republic of China, the Corporate Governance Code of The Stock Exchange of Hong Kong Limited, and other relevant regulations, taking the improvement of corporate governance as an important foundation for long-term development. By continuously strengthening the governance functions of the Board of Directors, clarifying the boundaries of rights and responsibilities, and implementing operational and accountability mechanisms, it continuously enhances decision-making efficiency and supervision efficacy. The Chairman of the Board cooperates closely with various functional departments and regional representative offices to promote the efficient operation of the corporate governance structure, further improve the internal management and compliance mechanisms, and ensure that the Group develops steadily in a standardized, orderly, and sustainable direction.




As of April 2026, the Board of Directors of Yunkang Group comprised seven members, of which three were independent non-executive Directors, accounting for 42.9%. There was one female Director, accounting for 14.3%. Among the independent non-executive Directors, there was one female member. The Company has adopted the Board Diversity Policy to further enhance the decision-making efficiency of the Board of Directors and maintain a high level of corporate governance. Board appointments adhere to the principle of “meritocracy”, and diverse backgrounds and professional combinations are fully considered during the selection process.

Skills and Competencies of Board Members

The members of the Board possess extensive and diverse management and professional experience. All three independent non-executive Directors possess professional qualifications and have profound professional accumulations in multiple fields.

Including but not limited to:



The gender and age structure of the Board members are as follows:

Gender Structure of the Board



Male
6 persons



Female
1 person

Age Structure of the Board



Aged 30-50
1 person



Aged 51 and above
6 persons

Sound corporate governance is the cornerstone of Yunkang’s long-term steady development. The Board of Directors has established the Audit Committee, the Remuneration Committee, and the Nomination Committee. Each committee is led by independent non-executive Directors, responsible for executing the external performance evaluation of the Board, strengthening operational supervision and enhancing transparency, and ensuring that the rights and interests of all shareholders are effectively safeguarded.

Audit Committee	Remuneration Committee	Nomination Committee
Chaired by an independent non-executive Director	Chaired by an independent non-executive Director	Chaired by an executive Director
67% of the members are independent non-executive Directors	67% of the members are independent non-executive Directors	67% of the members are independent non-executive Directors

5.1.2 Internal Control and Risk Management

Yunkang strictly builds an internal control mechanism centered on risk control, adhering to the principle of “early warning first, prevention foremost”. It continuously improves the risk management system, integrates risk management into management responsibilities and supervision procedures at all levels, dynamically identifies and assesses operational risks and their changes, and adopts effective response and mitigation strategies to comprehensively enhance risk resilience.

Risk Management Structure


Board of Directors	The Board of the Group is fully responsible for risk management and internal control systems and reviews their effectiveness. It is responsible for assessing and determining the nature and extent of risks that the Group is willing to take to achieve its strategic objectives, and for establishing and maintaining an appropriate and effective risk management and internal control system
Audit Committee	The Audit Committee assists the Board in leading the management to monitor the design, implementation, and supervision of risk management and internal control systems. Under the authorization of the Board, it is responsible for the continuous supervision of the Group’s risk management and internal control systems, as well as an annual review of the effectiveness of the systems
Internal Control Department	The Internal Control Department analyzes and independently evaluates the adequacy and effectiveness of the Company’s risk management and internal control mechanisms. It assigns relevant personnel to be responsible for identifying and monitoring the Group’s risks and internal control matters, and reports directly to the Audit Committee on any findings and follow-up actions

In addition, Yunkang promotes the building of an integrity and compliance culture through the Supervision and Management Measures to prevent major risks and safeguard the legitimate rights and interests of all stakeholders. The Company has established a dedicated supervision authority to standardize supervision workflows, which is coordinated and executed by the Legal and Supervision Department to ensure the effective implementation of supervision duties. Meanwhile, the Company clearly defines the employee code of conduct in the Employee Handbook, implements a zero-tolerance policy against violations, and adopts corresponding handling measures based on the severity of the circumstances, including warnings, disciplinary actions, or dismissal without compensation. The Company also provides compliance training for new employees and incorporates behavioral compliance into the performance appraisal system, comprehensively enhancing employees’ integrity awareness and compliance level from an institutional perspective.

Yunkang also attaches great importance to risk control and management optimization. The Group’s Guangzhou Medical Laboratory has passed the ISO 37301 compliance management system certification, further improving the enterprise’s compliance and internal control systems. During the Reporting Period, the Guangzhou Medical Laboratory was also audited by an authoritative third-party institution and was awarded the intellectual property compliance management system certification certificate in accordance with GB/T 29490-2023 Enterprise intellectual property compliance management system – Requirements.




Compliance Management System Certificate



Intellectual Property Compliance Management System Certificate

The Group continuously strengthens compliance management practices, providing legal opinions on key process links and business models through legal affairs reviews, and participating in special projects such as data compliance to promote the implementation of compliance requirements at the business level. At the same time, it led the launch of the 2025 corporate governance project, updated the annual risk assessment, and focused on reviewing the effectiveness of internal controls in specific areas, to further improve the internal control mechanism and enhance the overall governance quality and compliance level.

Yunkang implements major risk prevention and control mechanisms in a multi-dimensional manner, carrying out risk identification through daily process sorting, incident feedback, proactive information collection, and receiving complaints and reports, and conducts assessments on identified risks while actively implementing rectifications. During the Reporting Period, the Company did not experience any major risk incidents.



Internal Control and Risk Management Process

5.1.3 Anti-corruption and Anti-fraud

Upholding the core values of integrity and probity, Yunkang strictly complies with relevant laws and regulations such as the *Anti-Money Laundering Law of the People’s Republic of China* and the *Anti-Unfair Competition Law of the People’s Republic of China*. It has formulated institutional documents including the *Supervision and Management Measures of Yunkang Group*, *Yunkang Group Code of Conduct for Employees’ Business Behaviors*, *Yunkang Organizational Risk and Cadre Management Guidelines*, *Eight Regulations on Cadre Style Management of Yunkang*, and *Dedication and Self-discipline Declaration of Cadre of Yunkang*. All of these have been reviewed and approved by the Board of Directors, and are organized and implemented by the Group’s Legal and Supervision Department, thereby constructing a systematic anti-corruption and compliance framework.

To ensure the effective implementation of the anti-corruption and integrity system, Yunkang has established an anti-corruption governance structure composed of the Executive Committee and the Legal and Supervision Department, promoting the integration of an integrity culture throughout the entire process of corporate governance.



Whistleblowing Mechanism and Supervision Management

Streamlining Whistleblowing Channels The Group continuously strengthens corporate governance and internal controls to ensure compliant and honest operations. Yunkang encourages employees and stakeholders to report violations or improper behaviors through diversified whistleblowing channels, including a dedicated supervision email (jiancha@yunkanghealth.com), complaint and whistleblowing hotline, and customer service hotline. The dedicated email is managed by designated personnel responsible for receiving and processing relevant reports, ensuring timely responses and proper handling of information.

Strict Investigation Process The Legal and Supervision Department is responsible for collecting, verifying, and registering integrity complaints and whistleblowing information, and submitting cases to the Executive Committee for deliberation. Each case forms a report after investigation and evidence collection, which is then resolved by the Executive Committee and communicated in writing to the relevant personnel. If the subject of supervision has any objection, it may appeal, and the Executive Committee will make a final decision after a review. The Legal and Supervision Department follows up on the implementation of rectifications and completes the archiving process.

Whistleblowing Mechanism and Supervision Management

Whistleblower Protection The Company strictly protects the legitimate rights and interests of whistleblowers, explicitly prohibiting any retaliation, reprisals, or holding accountable of non-malicious whistleblowing behaviors, and ensures the security of whistleblowing information. The Legal and Supervision Department and relevant personnel are prohibited from disclosing whistleblowers' information. Upon discovery of any illegal disclosure or retaliatory behavior, strict disciplinary actions will be taken, and penalties such as warnings, demerits, or termination of employment will be imposed depending on the severity of the circumstances. At the same time, the Company has established a reward mechanism to commend or reward employees and relevant parties who provide important clues or make outstanding contributions to the investigation and handling of cases.

In addition, Yunkang continuously promotes the building of an anti-corruption and integrity culture, integrating the concept of probity throughout the entire process of corporate operations. In accordance with the Eight Regulations on Cadre Style Management of Yunkang, anti-corruption and integrity education has been incorporated into the training systems for Directors, employees, and partners, and integrity awareness is strengthened through oath-taking and specialized training. Meanwhile, suppliers are required to sign integrity agreements to prevent violations from the source. During the Reporting Period, Yunkang had no corruption litigation, nor any violations such as conflicts of interest, money laundering, or insider trading.

Benefiting from the well-established whistleblowing mechanism, supervision management, and the continuously promoted integrity culture building, the Group has achieved significant results in its integrity management system. Its Guangzhou Medical Laboratory has passed the GB/T 31950-2023 Integrity Management System certificate, and simultaneously obtained the GB/T 31863-2015 Enterprise Credit Rating AAA Grade certificate, fully reflecting Yunkang's outstanding performance in honest operations.



Integrity Management System Certificate



Quality Credit Evaluation Management System Certificate

5.2 SUSTAINABILITY GOVERNANCE

5.2.1 Board Statement

Yunkang has established a comprehensive ESG management framework that encompasses the decision-making level, management level, and execution level. The Company's Board of Directors, as the highest decision-making body, assumes full responsibility. To support the Board in performing its related duties, the Company has established an ESG Working Group, which is responsible for matters relating to ESG and climate change. The ESG Working Group is composed of members from the management and functional departments, and is headed by the Chairman of the Company, with the Securities Affairs Department, the CEO's Office, the Brand Promotion Department and the Legal and Supervision Department acting as executive leaders to assist the Chairman in overseeing the Company's ESG and climate change matters. The ESG Working Group reports regularly to the Board on ESG and climate change strategy, daily operations and risk management and the progress of ESG objectives on an annual basis.

Level	Department in Charge	Duty
Decision-making level	The Board	<ul style="list-style-type: none"> Resolving and overseeing the Company's ESG and climate change management approaches, strategies, policies, targets, and their progress, as well as ESG and climate change-related risks and opportunities, and the overall ESG agenda
Management level	ESG Working Group	<ul style="list-style-type: none"> Formulating ESG and climate change management approaches, strategies, policies, and targets, and identifying, assessing, and managing ESG and climate change-related risks and opportunities Enhancing the promotion and monitoring of the implementation of ESG and climate-related policies and initiatives across all relevant business lines, functional departments, and subsidiaries, thereby ensuring the integration of ESG and climate change strategies, targets, and initiatives into the Company's daily operations and business activities
Execution level	Heads of various platform departments	<ul style="list-style-type: none"> Organizing, advancing, and implementing various ESG and climate change initiatives in accordance with the Company's ESG and climate change management approaches, strategies, plans, annual work arrangements, targets, requirements, and division of responsibilities Collecting and reporting internal ESG and climate change policies, systems, and relevant performance indicators Complying with all ESG and climate change-related policies and systems Reporting regularly to the ESG Working Group

5.2.2 Stakeholder Engagement

Effective communication with stakeholders is key to enhancing corporate resilience and advancing sustainable development. Yunkang maintains close interaction with stakeholders through diversified channels, actively listens to their needs and responds in a timely manner. At the same time, the Company conveys its philosophy of corporate responsibility and the outcomes of its practices to stakeholders to deepen mutual trust and cooperation, thereby jointly promoting long-term value creation.


Stakeholders	Significance to Yunkang	Concerned Issues	Yunkang's Practice	Response Section
Hospital/ Customer	Focus on Yunkang's testing ability, quality and customer service	<ul style="list-style-type: none"> Compliant operations Product quality and safety Information security and privacy protection Customer service management Responsible marketing 	Continue to provide products and services with consistent medical testing quality and operate with integrity to enhance the satisfaction of hospitals and end consumers.	<p>5 Established On Integrity, Forging Ahead Steadily</p> <p>6 Excellence In Quality And Efficiency, Collaborative Progress</p>
Government and regulatory authorities	Supervise Yunkang's compliance with laws and regulations in medical testing and operation	<ul style="list-style-type: none"> Compliant operations Product quality and safety Information security and privacy protection Business ethics and anti-corruption Inclusive healthcare Industry cooperation and development 	Abide by laws and regulations, pay taxes in accordance with the law, continue to focus on government policies and assist in policy implementation.	<p>5 Established On Integrity, Forging Ahead Steadily</p> <p>4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation</p> <p>6 Advance Progress With Partners With Excellence In Quality And Efficiency</p>
Shareholders and investors	Focus on Yunkang's operating performance, corporate governance, and development	<ul style="list-style-type: none"> Compliant operations Product quality and safety Business ethics and anti-corruption Risk management Green operation 	Continuously improve corporate governance and ESG governance, create good results for the Company and bring returns to shareholders and investors.	<p>5 Seek Long-Term Success Building Upon Integrity</p> <p>6 Advance Progress With Partners With Excellence In Quality And Efficiency</p> <p>7 Pursue Sustainable Development Through Low-Carbon Practices</p> <p>Please refer to the annual report</p>

Stakeholders	Significance to Yunkang	Concerned Issues	Yunkang's Practice	Response Section
Employees	As the key human capital of Yunkang, employees are the foundation of Yunkang's continuous prosperity	<ul style="list-style-type: none"> Talent attraction and retention Employee training and growth Occupational health and safety of employees Employee rights and benefits 	Create a good working environment, expanding opportunities for staff development and building a sustainable workplace.	8 Share Prosperity For All Through People-Centric Development
Suppliers/ Partners	Provide reliable medical equipment and services to ensure the operation of Yunkang's medical testing services	<ul style="list-style-type: none"> Technology and innovation Compliant operations Business ethics and anti-corruption Product quality and safety 	Regularly review the performance of suppliers to ensure that the products and services supplied by suppliers meet the requirements.	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation
Industry/academic institutions	Scientific support for Yunkang's testing R&D and innovation capabilities	<ul style="list-style-type: none"> Technology and innovation Industry cooperation and development Intellectual property protection 	Insist on science and technology and innovation, always pay attention to the cutting-edge information in the industry, deeply participate in and actively organize professional activities.	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation
Patients/ Community	The ultimate beneficiaries of Yunkang's services and social responsibility, a wide range of social groups	<ul style="list-style-type: none"> Community public welfare and health Inclusive healthcare 	Uphold the beautiful vision and concept of "Healthy Community • Healthy Family", deeply explore the needs of the public health, and continue to carry out public welfare practice.	9 Care For The Community With Benevolence
Media	Media coverage has a profound impact on Yunkang's corporate brand image and reputation	<ul style="list-style-type: none"> Greenhouse gas emissions and management Waste liquid and water management Use and management of water resources Waste management Protection of the environment and natural resources 	Practice the concept of green and low-carbon development, promote environmental protection, optimize resource management, and reduce emissions.	7 Pursue Sustainable Development Through Low-Carbon Practices


5.2.3 Materiality Assessment

Yunkang attaches great importance to ESG materiality assessment, regularly conducting assessment/review work on an annual basis to comprehensively identify the impact of various ESG issues on the Company’s business development and the degree of attention they receive from stakeholders. During the Reporting Period, Yunkang completed the materiality assessment review, adopted targeted improvement measures based on the results, continuously optimized the ESG management system, enhanced the comprehensiveness and transparency of information disclosure, and continuously advanced the sustainable development process of the Group.

The process of the 2025 materiality review of Yunkang Group is as follows:



The results of the Group's 2025 materiality review are as follows:




Environmental Issues	Social Issues	Governance Issues
1 Greenhouse Gas Emissions and Management	10 Talent Attraction and Retention	27 Compliant Operations
2 Exhaust Emission and Management	11 Employee Rights and Benefits	28 Technology and Innovation
3 Waste Liquid and Wastewater Management	12 Diversity and Equal Opportunities	29 Stakeholder Communication
4 Waste Management	13 Occupational Health and Safety of Employees	30 Risk Management
5 Energy Use and Management	14 Employee Training and Growth	
6 Use and Management of Water Resources	15 Labour Standards	
7 Protection of the Environment and Natural Resources	16 Supply Chain Management	
8 Addressing Climate Change	17 Product Quality and Safety	
9 Green Operations	18 Customer Service Management	
	19 Intellectual Property Protection	
	20 Information Security and Privacy Protection	
	21 Responsible Marketing	
	22 Digital Operations	
	23 Business Ethics and Anti-corruption	
	24 Industry Cooperation and Development	
	25 Inclusive Healthcare	
	26 Community Public Welfare and Health	

No.	Material Issues	Values	Actions and Objectives	Response Section
17	Product quality and safety	“Quality is the lifeline.” Product and service quality represent the personality and dignity of Yunkang people	Implement various rules and regulations to achieve high-quality management of medical testing	6 Advance Progress With Partners With Excellence In Quality And Efficiency
28	Technology and innovation	The nation implements an innovation-driven development strategy, and innovation is an important means for enterprises to build their core competitiveness	Strengthen Yunkang’s core competitiveness, continuously promote product, technology, and service innovation, and provide medical testing services that align with market trends	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation
10	Talent attraction and retention	Employees are the important capital of the Company and the source of power for realizing its long-term development	Provide internally fair and externally competitive compensation and benefits, retain outstanding talents, and cultivate more talents	8 Share Prosperity For All Through People-Centric Development
27	Compliant operations	Compliant operations are the foundation of an enterprise and contribute to realizing Yunkang’s sustainable development	Establish sound business behaviors and ethical standards, ensure Yunkang’s sustainable operations, avoid illegal or improper transfer of benefits, and reduce operational risks	5 Seek Long-Term Success Building Upon Integrity
13	Occupational health and safety of employees	Daily safety prevention and management at operational premises help reduce the occurrence of accidents and property losses, and improve the production efficiency and economic benefits of the enterprise	Provide a healthy and safe working environment for employees and make every effort to safeguard their physical and mental health	8 Share Prosperity For All Through People-Centric Development
24	Industry cooperation and development	As technology continues to update and iterate, enterprises need to maintain an open posture, actively seek external complementary resources, and enhance their competitive advantages through collaborative innovation	Continuously follow cutting-edge industry discussions, and deeply participate in and actively organize professional activities	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation

No.	Material Issues	Values	Actions and Objectives	Response Section
18	Customer service management	An effective customer communication mechanism is conducive to optimizing customer service management, enhancing customer experience, and strengthening Yunkang's market competitiveness	Continuously enhance customer service capabilities, balancing the business model of revenue and sustainable development	6 Advance Progress With Partners With Excellence In Quality And Efficiency
16	Supply Chain Management	Supply chain management helps improve efficiency, reduce risks, and promote sustainable development and brand value growth	Strengthen supply chain management, strictly screen suppliers, and reduce environmental and social risks in the supply chain	6 Advance Progress With Partners With Excellence In Quality And Efficiency
21	Responsible marketing	Safeguarding the legitimate rights and interests of consumers can gain more customer trust and enhance the Company's brand image	Ensure that product publicity complies with the requirements of the Advertising Law	6 Advance Progress With Partners With Excellence In Quality And Efficiency
14	Employee training and growth	Focus on the sustainable development of employees and assist them in realizing their personal career value	Provide comprehensive training courses for employees, enabling them to grow together with the enterprise	8 Share Prosperity For All Through People-Centric Development
20	Information security and privacy protection	Protecting customers' personal information is the cornerstone for an enterprise to create long-term value	Enhance employees' information security awareness, strengthen data and cybersecurity protection, and avoid the leakage of customer information	6 Advance Progress With Partners With Excellence In Quality And Efficiency
9	Green operation	Enterprises achieving green operations is an inevitable requirement for implementing the concept of green development and a vivid practice of ecological civilization construction	Execute electricity conservation from daily operations, save energy consumption through energy-saving measures, and reduce the Company's operating costs	7 Pursue Sustainable Development Through Low-Carbon Practices

ESG Risk Identification and Assessment

Yunkang has formally integrated ESG risk management into its existing risk management and internal control system, and regularly conducts assessment/review work on an annual basis to effectively identify, assess/review, prioritize, and manage significant ESG risks relevant to the Group’s business. During the Reporting Period, Yunkang carried out the ESG risk review work, with the specific process as follows:



Based on the ESG risk assessment results, the Group identified the following ESG risks (with a risk level of “Medium”) that are crucial to operations and business during the Reporting Period, and reviewed the relevant control measures to ensure that such risks are effectively controlled:

Significant ESG Risks	Corresponding Chapters for Management Measures	Management Measures
Customer Service Management Risk	6 Advance Progress With Partners With Excellence In Quality And Efficiency	<ul style="list-style-type: none"> By establishing a standardized customer service system and building a multi-channel customer communication and feedback mechanism, Yunkang ensures the timely collection and response of opinions Implementing closed-loop complaint management to ensure the efficient resolution of customer issues and the enhancement of customer satisfaction
Human Capital Development Risk	8 Share Prosperity For All Through People-Centric Development	<ul style="list-style-type: none"> In accordance with the Rank System Management Measures, dual promotion channels for professional and managerial tracks have been established to support technical talents in deeply cultivating their professional fields, provide a management development platform for employees with leadership potential, and build a diversified talent reserve Formulating the Internal Referral Management Measures to clarify reward standards, mobilize employees’ enthusiasm for referrals, broaden talent acquisition channels, and enhance recruitment efficiency and quality
Employee Occupational Health and Safety Management Risk	8 Share Prosperity For All Through People-Centric Development	<ul style="list-style-type: none"> Establishing a comprehensive occupational health and safety management system, formulating and implementing internal systems, obtaining the ISO 45001 occupational health and safety management system certification, and continuously ensuring stable operation and optimizing improvements Organizing sports activities and mental health lectures, providing stress relief and emotion management guidance, and focusing on the comprehensive physical and mental health of employees

Significant ESG Risks	Corresponding Chapters for Management Measures	Management Measures
Compliant Operations Risk	5 Seek Long-Term Success Building Upon Integrity	<ul style="list-style-type: none"> Establishing a risk control system fully overseen by the Board of Directors, assisted in supervision by the Audit Committee, and independently evaluated by the Internal Control Department, integrating risk management into management responsibilities and supervision procedures at all levels Clarifying codes of conduct in the Employee Handbook, implementing a zero-tolerance policy against violations, and incorporating compliance into performance appraisals and new employee training
Medical Service Accessibility Risk	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation 9 Care For The Community With Benevolence	<ul style="list-style-type: none"> Adding new pathology laboratories and co-built sites, reaching out to western and grassroots medical institutions, building a remote pathology collaboration network, and extending high-quality pathology resources from major cities to remote and rural areas Extensively promoting health science popularization, disease screening, complimentary physical examinations, and charitable clinical diagnostic activities, covering multiple fields such as traditional Chinese medicine, chronic disease management, and children’s and elderly health, delivering professional medical services to the grassroots front line, and enhancing public health awareness and safeguarding levels
Technology and Innovation Risk	4 Maintain Leadership In Health Sector Through Intelligence-Driven Innovation	<ul style="list-style-type: none"> Pioneering the medical testing joint innovation platform, cooperating with dozens of medical institutions nationwide, and promoting the clinical transformation of scientific research achievements Taking the digital “cloud” systems as the core to advance full-scenario digital and intelligent operations Implementing the embedded AI chromosome analysis system, upgrading the AI Pathology Platform 2.0, and realizing the full-process digitalization and intelligentization of pathology testing

Significant ESG Risks	Corresponding Chapters for Management Measures	Management Measures
-----------------------	--	---------------------

Supply Chain Management Risk	6 Advance Progress With Partners With Excellence In Quality And Efficiency	<ul style="list-style-type: none"> Building a whole-industry-chain supply chain service platform, linking upstream and downstream to realize the integrated cooperation of industry, academia, research, supply, production, and sales, and integrating global resources to empower medical institutions and industry development Establishing dedicated risk control mechanisms for imported products, cold chain transportation, and special commodities, and setting up dedicated warehouses and emergency systems to cope with sudden risks
------------------------------	--	---

In addition, during the Reporting Period, by analyzing internal and external environmental factors such as changes in industry policies and technological innovation trends, Yunkang identified emerging risks related to its business, and formulated management measures based on the probability of risk occurrence, the degree of impact, and its own risk tolerance, so as to continuously improve the risk response system.

Name of Emerging Risk	Description	Management Measures
-----------------------	-------------	---------------------

Overseas Economic Sanctions Risk	Against the continuously evolving global geopolitical and cross-border regulatory landscape, cross-border business, overseas cooperation and upstream and downstream supply chains are exposed to potential compliance risks relating to international economic sanctions and export control requirements. Such risks may adversely affect business operations, cooperation development and corporate reputation. The Company continuously incorporates overseas sanctions compliance into the scope of ongoing emerging risk monitoring.	<ul style="list-style-type: none"> Continuously optimize cross-border sanctions compliance policies and response procedures, clarify accountability and risk escalation mechanisms, under the oversight of the risk and compliance departments. Conduct pre-entry compliance due diligence for new markets, businesses and counterparties, and screen relevant entities and transactions against international sanctions lists to avoid high-risk exposure. Maintain ongoing supply chain monitoring, conduct periodic risk assessments on business partners, and dynamically track changes in sanctions policies. Provide regular compliance training to raise risk awareness, and review the effectiveness of control measures through annual risk reviews.
----------------------------------	---	---


6 ADVANCE PROGRESS WITH PARTNERS WITH EXCELLENCE IN QUALITY AND EFFICIENCY

Yunkang has always adhered to the philosophy that “*quality is the lifeline*”, establishing a quality management system covering the entire process, strictly monitoring various links such as R&D, procurement, and services, and ensuring compliance with regulatory and industry standards. Adhering to the principle of continuous improvement, the Group continuously optimizes its quality supervision mechanism, is committed to providing professional, precise, efficient and convenient medical and healthcare services, and maintains industry-leading quality performance.

6.1 DUAL-DRIVEN OPERATIONS OF QUALITY AND EFFICIENCY

Yunkang has strictly complied with the *Interim Measures for Medical Laboratory Management*, the *Primary Standards and Management Specifications for Medical Laboratory (Trial)*, the *Primary Standards and Management Specifications for Pathology Diagnostic Center (Trial)* and other laws and regulations and industry standards. At the same time, Yunkang continuously improves its laboratory quality and medical cold chain management systems, and regularly reviews and examines their effectiveness through the Quality Management Committee, driving the continuous optimization of the systems to ensure that every test and service is reliable and accurate, demonstrating a brand commitment to professionalism and responsibility.

During the Reporting Period, through the joint efforts of all employees, the quality targets were comprehensively achieved.



6.1.1 Institutionalized Quality Control System

Yunkang builds the cornerstone of quality with institutions, systematically formulating internal systems including the *Quality Manual*, *Pre-examination Quality Control Procedures*, *Performance Verification and Validation Procedures for Examination Methods*, and *Quality Assurance Procedures for Testing Results*. These embed quality requirements throughout the entire testing process and standardize various quality management activities. The Company implements full-link quality control procedures to ensure the efficient operation of the system, and builds a traceable quality control barrier through multi-dimensional strengthening measures:

Prevention initiatives

- Establishing internal procedures such as the *Non-conforming Items Identification and Control Procedures*. Through systematic analysis and risk assessment, potential quality hazards are identified in advance, and preventive measures are taken to eliminate or reduce the occurrence of problems, thereby continuously optimizing the quality management system.

Criticality and exception management mechanism

- Establishing a criticality and exception management mechanism covering all qualitative and quantitative tests, timely recording abnormal test data, and continuously optimizing laboratory testing processes to ensure the timeliness and accuracy of clinical decision-making.

Proactively participate in external quality assessment

- Actively participating in external quality assessments organized by authoritative institutions such as the Clinical Laboratory Center of the National Health Commission, implementing full-process monitoring of EQA results, and initiating corrective procedures immediately upon any deviation from control standards;
- For non-assessed items, ensuring the reliability of test results through inter-laboratory comparison tests or sample exchanges with other laboratories.

Record all quality control results and comparison activities

- Recording and archiving all quality control results and comparison activities. In the event of out-of-control quality situations or clinically unacceptable comparison results, emergency corrective measures are immediately initiated, and complete rectification records are retained to form a traceable quality closed loop.

6.1.2 Escorted by Authoritative Certifications

Yunkang is committed to integrating international standards into its corporate operations, actively obtaining authoritative domestic and international certifications, and driving laboratory construction towards world-class levels. So far, the Company has independent laboratories in multiple key provinces and municipalities that have obtained dual accreditations from ISO 15189 and CAP, demonstrating its professional capabilities and quality strength. Among them, Yunkang Guangzhou Medical Laboratory and Chengdu Medical Laboratory have passed the ISO 15189 accreditation for 15 consecutive years and 12 consecutive years, respectively. Meanwhile, Hefei Medical Laboratory also successfully passed its re-accreditation in 2025. This fully highlights our continuous strengthening of testing quality and professional capabilities, providing a solid guarantee for clinical diagnosis services.




- Exporting Standardized Services Externally to Empower the Quality Upgrade of Medical Institutions**

Yunkang provides standardized system certification services for medical laboratories to co-built hospitals and third-party cooperative clients. For medical institutions that have not yet met the accreditation requirements of CNAS and ISO 15189, it assists them in starting with CLSI certification, gradually establishing a standardized quality management system, and laying the foundation for subsequent ISO 15189 accreditation. In 2025, the Group had promoted institutions such as Panyu Central Hospital, Dongguan Shilong Hospital, and Guangji Hospital to carry out standardized construction. Among them, Panyu Central Hospital successfully passed the ISO 15189 accreditation, and Guangji Hospital also completed the CLSI system certification at the beginning of the year, leveraging its professional capabilities to assist in the continuous improvement of the industry's quality level.



6.1.3 Empowerment through Co-building of Standards

Yunkang actively participates in national and provincial external quality assessments. Through a comprehensive EQA management mechanism, it encourages its subordinate laboratories to participate in proficiency testing projects organized by authoritative organizations such as the National Center for Clinical Laboratories (NCCL) of the National Health Commission and the China National Accreditation Service for Conformity Assessment (CNAS), continuously enhancing its professional strength.



During the Reporting Period, Yunkang's Guangzhou Da'an Clinical Laboratory Center participated in a total of 487 external quality assessment items with a participation rate of 100%, of which 480 items were qualified, representing a pass rate of 98.56%. Its Guangzhou Medical Laboratory participated in a total of 1,009 provincial-level and above external quality assessment items, of which 996 items were passed with perfect scores.

External Quality Assessment Items Participated in 2025:



6.1.4 Driven by Lean Management

Through the implementation of “7S” on-site management, Yunkang has achieved full-process standardization from specimen collection to report issuance. It has formulated quantifiable and replicable standard operating manuals, continuously optimized laboratory operation processes, and ensured that products and services always comply with standardization requirements.



On-site Management Case: Yunkang’s “7S” Management

SEIRI

SEITON

SEISO

SEIKETSU

SHITSUKE

SAFETY

SAVE



Rectification of the data processing area



Rectification of the operation and office areas

6.1.5 Strengthening Talent Development

Yunkang attaches great importance to the development of professional talents. Through a system that equally emphasizes training and assessment, competency certification, and innovation incentives, it drives the simultaneous enhancement of the team’s professional capabilities and innovative vitality. For laboratory personnel, the Company, together with the Human Resources Center, has jointly established the “Yunkang Professional Competency Assessment System for Medical Testing Positions” system. It conducts tiered and graded training and assessments from the aspects of theoretical knowledge, practical skills, quality management, and innovation capabilities, forming an efficient talent pipeline.

Adhering to the management philosophy of “participation by all, continuous improvement”, Yunkang continuously promotes the reform of its operation system and employment model, significantly enhancing its core competitiveness in aspects such as quality, cost, and timeliness.

- **Empowered by the Lean System, Building a Professional Team for Continuous Improvement**

The Laboratory Operation Center strengthens talent development with the lean management system, constructing a “four-in-one” model of “training and empowerment, certification and promotion, supporting incentives, and culture shaping” to drive continuous improvement among all employees. In 2025, it held the “Yunkang Lean Operation Training Camp”, launched the pilot certification for “Lean Management Specialists”, issued the *Laboratory Lean Management Optimization and Innovation Incentive Plan*, and conducted quarterly selections for outstanding lean proposals, setting benchmarks and promoting the implementation of lean culture.

- **Yunkang CLSI Auditor Training Class**

In June 2025, in accordance with ISO 15189 and CAP standards, Yunkang held the third CLSI auditor training class. The training focused on core contents such as auditing methods and report writing. Nine technical backbones passed the assessment and obtained auditor qualifications, comprehensively enhancing quality management capabilities, and promoting the international alignment of the laboratory system and the high-quality development of diagnostic services.



- **Responding to Regional Regulatory Requirements, Conducting Compliance Training on Outsourced Sample Testing**

In response to the *Compliance Guidelines for the Management of Outsourced Sample Testing by Medical Institutions in Shenzhen (Trial)* and the compliance requirements of hospital clients in Shenzhen, Yunkang conducted special compliance training in December 2025. Hosted by the Legal and Supervision Department, the training covered the compliance management requirements for the entire process of outsourced samples. The training covered relevant departments at the headquarters as well as personnel in Shenzhen sales, on-site technical support, and logistics fieldwork, strengthening the team's awareness of compliant operations and service capabilities, and ensuring the legal and compliant execution of clients' outsourced sample testing business.



• The “Green Eagle Award” Leading Innovation, Stimulating Teams’ Vitality for Improvement

Yunkang leverages the “Green Eagle Award” to incentivize technological innovation and process optimization, resulting in the emergence of multiple innovative achievements. Pathologist team developed an intelligent diagnosis dictionary, accelerating report entry by 64.5%, shortening the turnaround time by 6-8 hours, and standardizing 95.5% of the formats. Quality team implemented lean optimization for the serum vitamin ADE project, improving per capita efficiency by 94% and forming a replicable, highly efficient operation template, facilitating a dual increase in quality and efficiency.

6.1.6 Improving the Efficiency of Cold Chain Management

Based on an intelligent cold chain network, the Yunkang Logistics Center comprehensively standardizes sample transportation and management in accordance with standardized procedures such as the *Operation Procedures for Quality Control of Logistics*, the *Operating Procedures for Specimen Transport and Handover in Logistics*, and the *Operating Procedures for the Use and Temperature Control of Specimen Boxes in Logistics*. The Company continuously optimizes in-transit monitoring and temperature control management to ensure that sample transportation is efficient, safe, and traceable.

In accordance with the requirements of international standards such as ISO 15189 and CAP, Yunkang has improved its cold chain logistics system, becoming a drafting and pilot unit for the *Operational Specification for Cold Chain Logistics of Medical Laboratory Biological Samples*, and a pilot unit for the *Operation Specifications for Medical Product Cold Chain Logistics*. Relying on the intelligent medical logistics platform, it provides professional and reliable medical cold chain services for medical units in various regions across the country. Simultaneously, it achieves full-process monitoring and continuously optimizes the quality and safety management of sample in-transit transportation, providing high-quality cold chain services for medical institutions nationwide. In 2025, Yunkang obtained the certification of a compliant enterprise for the national standard GB/T 42186-2022 *Operational Specification for Cold Chain Logistics of Medical Laboratory Biological Samples*.



Certificates of Compliance

During the Year, Yunkang continued to advance intelligent temperature control and digital logistics management, building intelligent benchmark routes covering over 100 cooperative hospitals nationwide, and enhancing the efficiency and quality of medical logistics services through digital and intelligent capabilities. In terms of innovative transportation, the Company has actively explored application scenarios of the low-altitude economy and successfully launched the first ultra-long drone medical sample transportation pilot route in the Guangdong-Hong Kong-Macao Greater Bay Area. With a single-trip route length of 82.9 kilometers, passing through the three cities of Zhuhai, Zhongshan, and Guangzhou, it has achieved the safe, efficient, and cross-regional transportation of medical samples.

6.2 ENHANCING SERVICE QUALITY

Adhering to the philosophy of “full-scenario products” and “in-depth services”, Yunkang continuously improves its comprehensive operational system and high-quality service network. In the process of providing medical testing services, it focuses on clinical demand orientation and provides professional solutions tailored to the core needs of customers, achieving a win-win situation for both market value and customer value.

6.2.1 Service Capacity Building

In 2025, the Company had a total of over 3,800 testing items, including over 800 pathology testing items, with an annual tested specimen volume exceeding ten million cases. Currently, it has established a service network covering approximately 200 cities across 31 provinces and autonomous regions nationwide, providing professional testing services for over 1,500 medical institutions cooperating in medical institution alliances.

Against the backdrop of the nation’s continuous promotion of healthcare reform and the optimized layout of medical resources, Yunkang actively engages in medical institution alliances co-building cooperation with leading provincial hospitals and county-level general hospitals in various regions, serving as a professional link between regional testing centers and cooperative hospitals. The Group not only provides technical system support for cooperative institutions but also builds a full-process in-depth service system, covering the operation of regional medical institution alliances diagnosis centers, the introduction of new technologies and products, digital specialty construction, medical cold chain logistics, quality control, and supply chain services, thereby empowering the capability enhancement and long-term development of hospitals with professional and standardized services.


- **Introducing Intelligent Diagnostic Equipment to Promote the Upgrade of AI-Assisted Testing Technology**

Yunkang introduced an intelligent slide scanning and imaging system applied to the cytogenetic diagnosis and analysis process, effectively reducing reliance on manual operations and significantly improving testing efficiency and diagnostic accuracy. It further promotes the scenario-based application of AI-assisted diagnosis in the field of cytogenetic testing, continuously strengthening testing service capabilities through technological innovation.



6.2.2 Service and Quality Management

Yunkang strictly complies with laws and regulations such as the *Law of the People's Republic of China on the Protection of Consumer Rights and Interests*, and refers to the ISO 15189 standard to establish a comprehensive customer service and complaint handling process. Externally, Yunkang attaches importance to customer satisfaction surveys, promptly identifies service pain points, and rapidly implements improvements. Internally, Yunkang focuses on service standardization and the enhancement of the team's professional capabilities, continuously optimizing the customer service experience. The Company's Guangzhou Clinical Laboratory has been awarded the Five-Star Certificate of the After-Sales Service System under GB/T 27922-2011, highlighting Yunkang's outstanding performance and commitment in the field of customer service.



Five-Star Certificate of After-Sales Service System

- **Customer Satisfaction Survey**

Through customer satisfaction surveys, Yunkang identifies opportunities for improvement regarding the core service quality of laboratories, logistics, and customer service. Based on the survey results, it continuously optimizes the project management system and service processes, enhances the overall service level, consolidates customer trust, and expands the scale of cooperation.

The survey covers aspects such as service attitude, testing quality, and professional technology. Through telephone follow-ups with clinicians and doctors in the medical laboratories of cooperative hospitals, it collects ratings and suggestions, and records the feedback in detail. In 2025, Yunkang's customer satisfaction reached 95.75%.



- **Customer Consultation and Complaint Handling**

Yunkang has formulated and implemented the *Customer Consulting and Feedback Management Procedure* and the *Customer Feedback Processing Procedures* to standardize the processing flow for customer consultations, complaints, and appeals, clarify the responsibilities of each department, and ensure the continuous improvement of service quality. The Company has also established a national customer service center staffed with a professional team, which accepts customer opinions and complaints through multiple channels such as hotlines, emails, WeChat official accounts, and in-person visits, ensuring rapid response and proper handling.

In 2025, the Company received a total of 152 customer complaints, among which 18 cases were deemed valid, all of which have been properly resolved, achieving a resolution rate of 100%. Confirmed through follow-up visits, customer satisfaction with the handling of these incidents also reached 100%.

CUSTOMER COMPLAINT HANDLING PROCESS



- **Strengthening the Management of Customer Service Personnel**

Yunkang continuously strengthens the management of customer service personnel through multiple aspects such as standardization, training, and performance management, constantly enhancing employees' service quality and professional level, and stimulating their enthusiasm and initiative.

Service Standardization Norms

The Group has formulated the *Operational Procedures for Handling Result Enquiry of Customer Service Department*, the *Operating Procedures for Project Consultation Handling in the Customer Service Department*, and the *Language Standards for Customer Service Operator*, to promote standardized operations in links such as inquiries, consultations, and replies, unify professional terminology and service etiquette, and strictly abide by the requirements of customer privacy and information security.


Service Quality Training

A unified training system has been established to regularly conduct service training for all customer service staff and new employees. The content covers rules and regulations, standard operations, testing knowledge, and communication skills, integrating theoretical explanations, practical drills, and case studies. In 2025, the Company's customer service center completed a total of 19 training sessions, with an assessment pass rate of 100%.

Service Reward and Punishment Management

Following the principle of "emphasizing spiritual encouragement and ideological education, supplemented by performance-based punishment", it has formulated the *Customer Service Department Rewards and Punishments System*, and providing monthly performance score additions and commendations to employees with outstanding performance. Violations in links such as work order recording, inquiries, consultations, and feedback are handled in accordance with the regulations to ensure stable service quality.

• **Implementation of Customer Service Training**



6.2.3 Responsible Marketing

Yunkang adheres to the concept of responsible marketing, strictly complies with laws and regulations such as the *Advertising Law of the People's Republic of China*, and has established a full-process marketing compliance management system covering bidding, pricing, contract approval, and business execution. In accordance with internal systems such as the *Guidelines for Standardized Bidding Operations of Daan Clinical Laboratory* and the *Norms for Commercial Contract Management of Yunkang Group's Hospital Business Line*, the Company has set clear red lines and approval mechanisms for bidding behaviors, contract signing, and quotation processes. It strictly prohibits violations such as bid rigging, fraud, material forgery, and exceeding authorization for approval, ensuring that marketing activities are legal and compliant.

In contract and quotation management, the Company clarifies the approval responsibilities of multiple positions, emphasizes accurate cost accounting and risk prevention and control, and promotes price transparency and fair competition. Yunkang continuously conducts compliance and business ethics training, requiring employees to strictly abide by the principles of integrity, comply with industry norms, and put an end to any behaviors that violate medical ethics or improperly influence cooperation decisions.

6.2.4 Customer Privacy Protection

Yunkang attaches great importance to customers' personal information and data security, strictly complying with laws and regulations such as the *Cybersecurity Law of the People's Republic of China*, the *Personal Information Protection Law of the People's Republic of China* and the *Data Security Law of the People's Republic of China*. The Company has established a full-process and full-scenario information security and privacy protection mechanism to ensure that trade secrets and customer privacy are not leaked.

• Information Security Management System

By formulating the *Yunkang Group Information Security Management Measures*, Yunkang promotes and implements the following commitments:

- Regularly conducting information security inspections, security vulnerability remediation, continuously optimizing systems, and conducting security hardening to ensure the continuous improvement of the information security system;
- Legally protecting data from being destroyed, altered, or leaked, maintaining the integrity, confidentiality, and authenticity of information, comprehensively covering the protection of customer information, health information, testing data, and trade secrets; and
- Establishing handling procedures for emergency information security incidents, regular security inspections, real-time responses, on-site handling, liaison for government inspections, vulnerability remediation, and emergency response mechanisms to effectively monitor and respond to information security threats.

Based on this, the Company also implements a system of unified leadership and hierarchical management. In accordance with the principle of "whoever is in charge is responsible, and whoever uses is responsible", responsibilities are implemented level by level. Information security and privacy security responsibilities are explicitly refined to departments and individuals, and all employees must abide by confidentiality norms, thereby establishing a personal information security responsibility system covering all employees:

Group CEO	The highest person in charge of the Company's information security, responsible for decision-making regarding major or emergency information security incidents
Executive head of information security	Coordinating and managing the information security inspections and emergency information security incidents of the Group and the laboratories, and synchronizing relevant progress to the persons in charge of the laboratories and representative offices
Information security administrators	Responsible for the implementation of information security inspections for the Group and local laboratories, the rectification of results and security vulnerabilities, and handling emergency information security incidents from a technical perspective
Regional or subsidiary information security officers	The person in charge of the representative office or the subsidiary acts as the first person in charge. In the event of a major incident, it is necessary to closely track with government agencies and promptly report back to the Group

The Group's information security management structure also covers privacy protection matters. At the same time, the Company has established a standardized emergency and reporting mechanism for information security incidents. In the event of a major information security incident, the Information Center, together with the regional or subsidiary information security officer, will report to the President of the Group and the Executive Committee immediately, and quickly activate the response plan.

In addition, we have passed multiple authoritative certifications, including the Level 3 Certification of National Information Security Grade Protection, SPCA Certification, and ISO 27001 Information Security Management System, covering application software development, information security maintenance and management, etc., comprehensively safeguarding customer privacy and enhancing the level of security management. The Company conducts external audits and risk assessments annually in accordance with the ISO 27001 standard, including vulnerability scanning, manual audits, and penetration testing, to ensure the confidentiality, integrity, and availability of the information security system. In addition, the Company engages third parties to conduct simulated attack and defense drills, and conducts at least one internal audit annually to ensure the compliance of the management system. During the Reporting Period, the pass rate of the Company's information security risk assessment reached 100%.



Information Security Management System Certificate

• User Information Security and Privacy Protection

Yunkang attaches great importance to information security and privacy protection, and has formulated the *User Information and Privacy Protection Policy* to comprehensively regulate the collection, use, storage, and disclosure of customers' personal information. The Company adheres to the principles of "reasonable and necessary, fully informed, safe and reliable", and only collects information necessary for providing services. It ensures that customers are fully aware of how their information is processed and their rights, including the types and purposes of the collected information, the methods of data use, sharing, transfer, and public disclosure, as well as personal information protection and management measures, especially the information processing norms for minors. Customers can independently decide whether to provide relevant information. At the same time, it safeguards data security through multi-dimensional measures such as encryption technology, access control, and access auditing. Yunkang has passed the ISO 27701 Privacy Information Management System Certification. The Company regularly conducts internal and external audits and employee training, and integrates privacy management into risk control and daily operations. In the event of a security incident such as information leakage, the Company will activate the emergency plan, handle it swiftly, report it promptly, and inform customers of the relevant circumstances and protective recommendations in accordance with the law.



Information Technology Service Management System Certificate

- **Strengthening Employee Management**

Yunkang has formulated and regularly updates the *Regulations on the Management of Rewards and Punishments for Information Security*, clarifying management responsibilities at all levels and incorporating information security into the employee performance appraisal system. It implements a penalty mechanism for information security violations, fulfilling the requirement of zero tolerance. When an information security incident occurs, the Company imposes administrative or economic penalties based on the nature of the incident, the scope of impact, and the severity of the consequences, and holds those who intentionally cause damage and result in serious consequences legally liable in accordance with the law.

The Company strictly implements system operation authorization and training requirements, and regularly conducts information security awareness promotion, cybersecurity thematic training, and emergency drills. In 2025, the coverage rate of information security and privacy training reached 100%, and no severe complaints related to customer privacy leakage or information loss were received.

6.3 IMPROVING INNOVATION MECHANISMS

Innovation is the core driving force for the sustainable development of an enterprise. In recent years, Yunkang has continuously improved its R&D system, stimulated the creative potential of its team, consolidated the transformation of scientific research achievements, and strengthened its intellectual property layout, continuously enhancing its technological innovation capabilities and core competitiveness, and injecting inexhaustible momentum into the high-quality development of the enterprise.

6.3.1 R&D Management System

Yunkang has established a comprehensive R&D management system and institutional framework, such as the *Research and Development Project Management Regulation*, *Research and Development Investment Accounting Management System* and *Management System of the Research and Development Center*, to comprehensively safeguard innovative R&D investment and strengthen the building of the R&D team. Through institutionalized and standardized management, Yunkang continuously enhances its technological R&D capabilities and management level, laying a solid foundation for the long-term sustainable development of the enterprise.



Management Process and Responsibilities of R&D Projects

Group CEO	Coordinate, review and approve annual R&D plans, and supervise and evaluate the implementation of the plans
R&D centers	Develop R&D project plans and design implementation plans, as well as launch the promotion and application of the transformation of scientific research results
Relevant departments	Provide suggestions for the R&D projects construction as a reference and assist R&D personnel management and cost monitoring

6.3.2 Stimulating Innovation Momentum

Yunkang takes high R&D investment as the core engine to drive continuous innovation. In 2025, the Company's R&D investment reached RMB51.9 million, continuously advancing the iterative upgrade of products and technologies, and providing strong technological support for medical institutions at all levels.



Yunkang has formulated and implemented mechanisms such as the *Performance Reward Management System for Research and Development Personnel*, *Organizational Implementation and Incentive Reward System for Achievement Transformation*. It comprehensively evaluates R&D performance from multiple dimensions such as technological content, advancement of indicators, and development difficulty, and provides financial rewards for achievements such as intellectual property rights, academic papers, new technologies, and new methods, thereby stimulating the enthusiasm and creativity of scientific researchers. At the same time, through the *Management System for the Introduction, Cultivation and Training of Talents*, it introduces high-end talents in the fields of molecular biology and bioinformatics, continuously injecting innovation momentum into the enterprise. As of the end of the Reporting Period, Yunkang had formed a specialized scientific research team composed of 89 scientific researchers, providing solid support for technological innovation and industrial upgrading.

In addition, *Yunkang officially launched the Laboratory Lean Management Optimization and Innovation Incentive Plan of Yunkang Group* in 2025. Through targeted incentive mechanisms, it fully stimulates the initiative and creativity of all laboratory employees in proposing optimization and innovation plans in laboratory production, management, and service links.

6.3.3 Consolidating R&D and Innovation Achievements

Relying on its scientific research foundation and technological advantages, Yunkang continuously improves its scientific and technological innovation system, strengthens the transformation of achievements and intellectual property management, and enhances its core competitiveness. As the core leading construction unit of the National Genetic Testing Demonstration Center, the Company has passed the "National High-tech Enterprise" certification for the sixth consecutive time, demonstrating its robust innovation strength.

6.3.4 Intellectual Property Management

Yunkang has formulated the *Administration of Intellectual Property Rights* to strictly regulate the protection and management of scientific and technological research achievements, clarifying the intellectual property declaration process and division of responsibilities, and ensuring the institutionalization of management and the standardization of processes. At the same time, the Company has established an intellectual property project team to comprehensively coordinate and be responsible for the operation and management of intellectual property, safeguarding the effective protection and rational application of innovative achievements.

As of 2025, Yunkang cumulatively held 328 various types of patents and intellectual property rights, including 13 invention patents, 22 utility model patents, 104 software copyrights, and 189 trademarks. These achievements reflect the Company’s comprehensive strength in technological innovation, scientific research management, and intellectual property protection, further consolidating its capacity for continuous innovation and high-quality development.




Intellectual Property Compliance Management System Certificate

6.4 Deepening Ecological Synergy

Yunkang is committed to building a responsible and sustainable supply chain management system, continuously improving risk monitoring and partner synergy mechanisms. Through institutional innovation and technological platforms, the Company promotes the transparency, efficiency, and win-win development of the supply chain, fostering a virtuous cycle in the industry.

6.4.1 Building a Smart Supply Chain Platform

Yunkang actively builds a whole-industry-chain integrated supply, production, and marketing service system and a supply chain service platform, achieving efficient connection and resource sharing among R&D, production, and circulation. The Company links industry, academia, research, and upstream and downstream enterprises, integrating the technological and market advantages of global partners to provide integrated procurement and service support for medical institutions.



Yunkang Supply Chain Service Platform

6.4.2 Strict Control over Supply Chain Quality Management

Yunkang strictly complies with the *Tendering and Bidding Law of the People's Republic of China* and the requirements of the ISO 15189 standard, establishing a full life cycle quality management mechanism covering supplier admission, evaluation, dynamic management, and assessment. By formulating and implementing the *Procurement System of Yunkang Group*, and adopting a strategy combining centralized procurement and localized procurement, the Company adheres to the principles of openness and transparency, fair competition, impartial evaluation, honest operation, and efficiency priority, ensuring that procurement management and processes are safe, transparent, and compliant. We have also established a Procurement Committee responsible for the procurement project initiation approval, supplier evaluation, and commercial negotiation of major and new projects.

Yunkang manages suppliers in accordance with systems such as the *Supplier Management Procedure*, the *Operation Procedure for Supplier Evaluation and Selection*, and the *Operation Procedure for Supplier Evaluation*. The evaluation criteria cover cost, delivery timeliness, product quality and service, as well as whether suppliers comply with relevant laws, regulations, and standards, including requirements for quality and safety, business ethics, environmental protection, anti-corruption, information protection, and intellectual property. The above management system is applicable to all suppliers, ensuring that the Group's procurement process is transparent, efficient, and compliant.

Supplier Development

- Based on the QCDT (Quality, Cost, Delivery, Time) guidelines, we investigate the company qualifications, product qualifications, and market share of new suppliers, conduct on-site inspections of the suppliers, and form a written Supplier Survey Form

Supplier Admission Evaluation

- Select multiple suppliers according to the types of products, and require the suppliers to provide written supply plans
- Initiate sample and equipment trial applications for suppliers that pass the inspection, and form a Trial Report

Supplier Dynamic Management


- Form an evaluation panel to score the suppliers from dimensions such as quality, technology, and service. Those scoring above 60 points are included in the list of qualified suppliers, and are classified into four grades of A, B, C, and D from high to low according to their scores, to conduct scientific management by grade and category
- Sign contracts with the qualified suppliers, and the contracts explicitly stipulate the quality control clauses of the suppliers

Supplier Assessment

- An evaluation panel composed of the heads of relevant technical departments such as procurement, finance, and quality conducts at least one strict review annually on the qualifications, supply capacity, and product quality of the suppliers
- Suppliers whose evaluation results are below 60 points for two consecutive times will be eliminated

As of December 31, 2025, Yunkang had a total of 332 suppliers of various types, including 131 manufacturing enterprises and 201 non-manufacturing enterprises. The classification of suppliers by region is as follows:

Regional distribution of Yunkang’s suppliers:




Yunkang has formulated a regular evaluation mechanism for cooperative suppliers, and the user departments are responsible for evaluating the product quality of the suppliers. In 2025, the Company adopted a written assessment method to conduct annual evaluations on suppliers, involving types such as reagent consumables, equipment distributors, manufacturers, and service suppliers. A total of 115 suppliers were evaluated, accounting for 34.64%. During the Reporting Period, all suppliers passed the assessment.



6.4.3 Build a Responsible Supply Chain

Yunkang actively promotes the integration of ESG principles into supply chain management, guiding suppliers to jointly fulfill their responsibilities in the three major aspects of environment, society, and governance.



ENVIRONMENT AND CLIMATE

7

Pursue Sustainable Development Through Low-Carbon Practices



7 PURSUE SUSTAINABLE DEVELOPMENT THROUGH LOW-CARBON PRACTICES

Yunkang actively fulfills its environmental responsibilities, adheres to the concept of green and low-carbon development, continuously deepens the practice of ecological civilization, assists in achieving the national “dual carbon” strategic goals, and promotes the harmonious coexistence of economic development and the ecological environment.

7.1 PROMOTING GREEN OPERATIONS


Yunkang strictly complies with the *Environmental Protection Law of the People's Republic of China* and other relevant laws and regulations, as well as the environmental protection requirements of the medical and healthcare industry. Through measures such as establishing a sound environmental management system, improving resource utilization efficiency, and lawfully and compliantly disposing of various emissions, the Company promotes the continuous realization of low-carbon and green operations.

7.1.1 Environmental Management System

Anchored by the *Yunkang Group Environmental Management System* and the *Environmental and Occupational Health and Safety Management Handbook* as the core, Yunkang has established a comprehensive environmental management system. The General Manager is responsible for formulating and approving relevant policies, targets, and commitments, and bears the primary responsibilities for environmental and safety management, comprehensively implementing the duties of environmental and safety management, and promoting the coordinated progress of Yunkang's operations and environmental protection.

In 2025, Yunkang further improved the *Contingency Plan for Emergent Environmental Emergencies* and issued the *Risk Assessment Report for Environmental Emergencies*, comprehensively strengthening its capabilities in environmental risk identification, early warning, and emergency response, thereby enhancing the effectiveness of environmental management. At the same time, it conducts environmental protection advocacy and training, encouraging employees and partners to fulfill their environmental responsibilities through practical actions, and jointly creating a low-carbon, energy-saving, and sustainable working and development atmosphere.

During the Reporting Period, Yunkang’s Guangzhou Medical Laboratory successfully passed the ISO 14001 environmental management system certification, fully demonstrating the Company’s continuous investment and outstanding achievements in the professional and standardized construction of environmental management.



Environmental Management System Certificate

Environmental Goals

The environmental impacts of Yunkang’s business activities mainly include GHG emissions, waste generation, and energy use efficiency. Therefore, the Company has formulated environmental targets in these categories to promote responsible environmental management and reduce its environmental impacts.

Target Scope	Environmental Goals	Indicators	Action Plan	Action Plan Timeframe	Actions Taken During the Reporting Period	Target Achievement Progress
Greenhouse Gas Emissions	Improving the existing greenhouse gas emissions management system	Establishing a comprehensive data collection system	Identifying the main emission sources of Scope 1, 2 and 3 emissions, determining the data types and corresponding data to be collected, and establishing data collection lists and guidelines	Short-term Medium-term	Carrying out the data collection and accounting work for Scope 3 GHG emissions.	Completed
	Reducing greenhouse gas emissions	Encouraging green commuting	Advocating the concept of green commuting such as walking, cycling, and taking public transportation within the Company; minimizing business travel in first-class and business-class cabins	Short-term	Establishing convenient facilities such as bicycle parking areas and charging cabinets within the Company, and reducing business travel by car and business flights through travel requirements and administrative unified ticket booking.	Completed

Target Scope	Environmental Goals	Indicators	Action Plan	Action Plan Timeframe	Actions Taken During the Reporting Period	Target Achievement Progress
		Promoting informatization and digitalization	Improving operation and service efficiency and promoting energy conservation and emission reduction through the adoption of informatization and digitalization means	Medium-term Long-term	Promoting electronic customer services, including electronic billing, online signing, and remote support, to reduce carbon emissions caused by paper consumption and business travel; meanwhile, providing remote support for internal administration through digital processes such as online offices, to reduce carbon emissions brought by regional administrative/business travel.	Completed
Waste Generation	Conducting waste reduction at the source	Reducing domestic waste	Reducing the use of disposable items; purchasing an appropriate amount of food to reduce the generation of food waste and takeout garbage	Short-term	Implementing "green office" and "green dining" measures, such as providing employees with reusable tableware and water cups.	Completed
		Implementing green office to reduce paper use	Promoting paperless offices and using electronic documents instead of paper; promoting double-sided printing	Short-term Medium-term	Through IT-level technologies, presetting some project documents to double-sided and black-and-white printing.	Completed
	Increasing the waste recycling rate	Increasing the recycling and reuse rate of various types of waste	Identifying recyclable and reusable items, and arranging for their recycling or reuse elsewhere; arranging qualified recyclers to recycle various types of waste	Short-term Medium-term	Carrying out special recycling for specific waste, such as batteries and ink cartridges, through the trade-in requirements for applying for office supplies.	Completed
	Properly disposing of waste	Strengthening the collection and treatment of medical waste	Improving the medical waste management system and operating procedures to collect and treat medical waste reasonably and lawfully	Short-term Medium-term	Organizing and conducting special training to ensure that relevant personnel fully master the medical waste disposal procedures.	Completed

Target Scope	Environmental Goals	Indicators	Action Plan	Action Plan Timeframe	Actions Taken During the Reporting Period	Target Achievement Progress
Energy Use Efficiency	Reducing energy waste	Reducing energy consumption in offices and laboratories	Identifying high-energy-consuming equipment and gradually replacing it with high-efficiency energy-saving equipment; using/purchasing energy-saving equipment (such as LED lamps, energy-saving refrigerators, etc.); promptly turning off equipment, air conditioners, and lights, ensuring that lights and air conditioners are turned off when no one is present	Short-term Medium-term	Setting unified temperature and time control standards for the activation of equipment such as air conditioners and lighting, and arranging security guards and cleaning staff to conduct regular inspections daily to promptly turn off equipment, air conditioners, and lights.	Completed
	Improving energy use efficiency	Conducting energy management	Conducting energy audits to identify energy-saving opportunities, and continuously optimizing and improving workflows and daily operation management	Short-term Medium-term	Continuously improving energy use efficiency and reducing carbon emissions through intelligent equipment management, the adoption of high-efficiency energy-saving products, and the promotion of energy recovery and utilization.	Completed
	Using renewable energy	Increasing the utilization rate of renewable energy	Increasing the proportion of new energy vehicles in the logistics fleet	Long-term	Conducting quantitative statistics on relevant data after the increase in the proportion of the Company's new energy vehicles.	Completed
All Environmental Target Categories	Raising employees' awareness of environmental protection and conservation	Providing environmental protection training for employees	Incorporating environmental protection training into daily training; formulating environmental protection training/advocacy plans to regularly hold energy-saving and environmental protection activities	Short-term Medium-term	Establishing an annual environmental protection training and advocacy calendar.	In progress
		Setting up environmental protection promotion boards	Setting up environmental protection signs and promotional slogans at public facilities and equipment	Short-term	Setting up environmental protection signs and promotional slogans in areas such as laboratories.	Completed

7.1.2 Energy Management

Yunkang strictly complies with the *Energy Conservation Law of the People's Republic of China*. The Company has established a comprehensive environmental and energy management system. It also continuously monitors energy consumption and optimizes control strategies. The Company has issued the *Electricity Energy-Saving Management Measures of Yunkang Group*, specifying energy conservation requirements for each region, strengthening electricity use supervision, and reducing energy waste and environmental impacts. Through regular energy inspections and audits, it continuously explores energy-saving potential and promotes green, smart, and sustainable development.

Energy Conservation Optimization at the Management Level

- Establishing a green warehousing management system to reduce daily energy consumption through reasonable site selection and temperature control.
- Formulating electricity and air conditioning usage specifications, and setting appropriate temperatures for office and laboratory areas to avoid energy waste.
- Establishing a management mechanism combining employees' conscious energy conservation with administrative inspections to ensure that lights and air conditioners in unoccupied areas are turned off promptly.

Energy Conservation Improvements in Equipment and Technology

- Implementing intelligent management of high-energy-consuming equipment in laboratories, such as adjusting air conditioning temperatures and setting timed switches for equipment.
- Ensuring that equipment such as sterilizers, ovens, and cleaning equipment operates at full load to reduce energy consumption from idling.
- Procuring high-efficiency machinery and lighting equipment that meet energy efficiency certifications or intelligent energy-saving functions.
- Replacing traditional microscope mercury lamp light sources with LED light sources to reduce energy consumption and maintenance costs.

Energy Recovery and Renewable Utilization

- Utilizing the atrium photovoltaic canopy to collect solar energy and convert it into electrical power for laboratory operations.

Operation and Maintenance Management

- Regularly maintaining and repairing various types of equipment to maintain their optimal operating efficiency and extend their service life.
- Promoting green logistics by prioritizing the use of new energy vehicles for transportation to reduce carbon emissions.

In addition, the Company actively promotes energy conservation education and training, strengthens employees' environmental awareness and energy-saving actions through standardized and institutionalized measures, fully practices the green and low-carbon operational philosophy, and builds an energy-saving and efficient corporate culture.



During the Reporting Period, the Company's total direct and indirect energy consumption is as follows:

Energy	Unit	Data in 2025
Total Energy Consumption	Thousand kWh	4,807.83
Total Energy Consumption Intensity	Thousand kWh/million RMB	8.00

7.1.3 Water Resources Management

Yunkang attaches great importance to the protection and management of water resources, strictly complies with the *Water Pollution Prevention and Control Law of the People's Republic of China* and other relevant laws and regulations, and is committed to improving water use efficiency and promoting the sustainable utilization of resources. The Company optimizes water use management through multiple measures, including strengthening water use monitoring in office areas, laboratories, and parks, promoting water-saving equipment and efficient water use technologies, and enhancing employees' water-saving awareness and conscious actions by posting "Save Water" signs and conducting internal advocacy. At the same time, the Company regularly monitors water resources usage and water quality conditions to ensure that all water use behaviors comply with national environmental protection standards and industry norms, and utilizes digital management methods to continuously improve water resource utilization efficiency.

During the Reporting Period, the Company's total water consumption and water consumption intensity are as follows, and there are no problems in accessing applicable water sources:

Water Resources	Unit	Data in 2025
Total Water Consumption	Cubic Meter	8,600.20
Water Consumption Intensity	Cubic meter/million RMB	14.31

7.1.4 Emissions Management

Yunkang strictly complies with relevant laws and regulations such as the *Regulations on the Administration of Medical Wastes*, the *Measures for Medical Wastes Management of Medical and Health Institutions* and the *Regulations on the Safety Management of Hazardous Chemicals*. It has formulated and implemented internal systems such as the *Responsibility System for Control and Disposal of Hazardous Waste with Environmental Pollution*, the *Yunkang Medical Waste Classified Collection Management System*, and the *Standard Operating Procedures for Laboratory Medical Waste Disposal*, ensuring the compliant management and proper disposal of various emissions. By strengthening the management of medical waste liquid, wastewater, and waste gas, Yunkang is committed to reducing its environmental impacts.

Medical Waste Liquid Management

Yunkang strictly complies with laws and regulations related to medical waste liquid management, entrusts qualified third-party environmental protection agencies to professionally recycle and harmlessly treat medical waste liquid, and monitors the entire processes of collection, transportation, and reception to ensure compliance, safety, and transparency. At the same time, Yunkang has introduced solvent waste liquid recovery equipment in the pathology laboratory to recycle and reuse the xylene waste liquid generated during the testing process, reducing the risk of pollutant emissions from the source and promoting the recycling of resources.



Medical Waste Liquid Temporary Storage Room

Wastewater Management

Yunkang has established an internal wastewater treatment system and entrusts qualified third parties to assist in the disposal. The Company adopts advanced treatment equipment to effectively remove chemicals and harmful substances, ensuring that wastewater discharge meets the standards. At the same time, it regularly conducts water quality testing to continuously monitor treatment effectiveness and compliance.



Self-built Wastewater Treatment Facilities

Waste Gas Management

Yunkang adopts highly efficient technologies such as activated carbon adsorption to treat waste gas emissions, ensuring that pollutants are stably discharged up to standard after filtration. Meanwhile, the Company continuously screens and assesses equipment with high pollution risks, promptly eliminating or upgrading them to reduce emissions at the source and promote a clean and low-carbon operational model.



Waste Gas Treatment Equipment

7.1.5 Waste Management

Yunkang strictly complies with the *Law of the People’s Republic of China on the Prevention and Control of Environmental Pollution Caused by Solid Wastes*, implements the classified collection and refined management of waste, and adopts appropriate disposal measures for hazardous and non-hazardous waste respectively. At the same time, the Company continuously monitors the generation and destination of waste, establishes a sound daily generation recording mechanism, and actively seeks opportunities for reduction and resource utilization, continuously enhancing waste management efficiency and driving the enterprise towards green, circular, and sustainable development.

Hazardous Waste Management

The Company has formulated and implemented the *Medical Waste Classified Collection Management System*, the *Responsibility System for the Prevention and Control of Environmental Pollution by Hazardous Wastes*, and the *Hazardous Waste Management System*, establishing a full-process control system.

- Strict supervision is implemented throughout the entire process of generation, classification, labeling, storage, transfer, and disposal for hazardous wastes such as medical waste, waste toner cartridges, and waste ink cartridges, implementing the principle of “whoever generates is responsible”.
- Anti-seepage and anti-leakage facilities are equipped, and a transfer manifest system is implemented to ensure that hazardous waste management is safe, compliant, and traceable.
- Strictly following laws and regulations to construct, use, and maintain temporary storage sites for hazardous wastes, ensuring the compliant disposal of hazardous wastes.

2025 Medical Waste Reduction Achievements



Non-Hazardous Waste Management

- The Company’s non-hazardous waste mainly includes domestic waste from daily offices and general solid waste from operational processes.
- Domestic waste, after classification, is uniformly handed over to the environmental protection department for compliant disposal, among which recyclable materials are collected, recycled and reused by qualified third-party companies designated by the environmental protection department.
- The canteen no longer provides disposable lunchboxes for takeaways, and all use reusable tableware to reduce waste generation.
- Comprehensively practicing the *Yunkang Group 7S Work Implementation Handbook*, optimizing the office environment by improving waste management, thereby enhancing operational efficiency.

During the Reporting Period, the Company's waste generation is as follows:

Waste	Unit	Data in 2025
Total hazardous waste	Tonnes	181.59
Intensity of hazardous waste	Tonnes/million RMB	0.30
Total non-hazardous waste	Tonnes	34.57
Intensity of non-hazardous waste	Tonnes/million RMB	0.06

7.1.6 Green Operations Management

The Yunkang Logistics Center continuously advances low-carbon transformation and green operations, effectively reducing energy and resource consumption and improving transportation efficiency and environmental benefits through multiple specific measures.


Green Operations and Paper Reduction Actions	Green Transportation and Packaging Optimization	Exploration of Low-Altitude Economy and Innovative Transportation	Intelligent and Digital Management
<ul style="list-style-type: none"> Paperless reports are realized through system integration with clients, and internal manual registration is replaced by information systems within logistics, reducing the use of detailed lists. In 2025, paper usage was estimated to be reduced by more than 60,000 sheets per month, and printing costs are expected to be saved by approximately RMB10,000 per month, significantly lowering resource consumption and reducing carbon emissions. 	<ul style="list-style-type: none"> Promoting new energy vehicles as the main transportation tools, a total of 88 new energy vehicles were used in 2025, accounting for 70% of the total logistics vehicles, significantly reducing fuel consumption and carbon emissions. Packaging materials have been upgraded to high-density expanded polypropylene (EPP) incubators, currently reaching a 60% coverage rate in express transportation, effectively replacing easily consumable polyurethane (PU) material incubators, extending service life, and reducing waste volume. 	<ul style="list-style-type: none"> In July 2025, Yunkang Group, together with its partners, conducted a low-altitude medical sample transportation test and successfully completed a cross-city drone delivery task, marking the official landing of the first long-range medical low-altitude logistics route in the Greater Bay Area, significantly improving transportation timeliness and the level of green operations. 	<ul style="list-style-type: none"> Establishing a smart temperature control and digital monitoring system to create smart benchmark routes, covering over 100 Tier-2 and Tier-3 cooperative hospitals, achieving full-process smart monitoring and efficient medical logistics services.

7.2 ADDRESSING CLIMATE CHANGE

As the impacts of climate change become increasingly significant, tackling climate change is no longer merely an environmental issue, but an indispensable and important component of corporate sustainable development management. To implement the national “dual carbon” goals and relevant policy requirements, Yunkang has disclosed climate-related information from four pillars: “Governance”, “Strategy”, “Risk Management”, and “Metrics and Targets” since 2023. In 2025, Yunkang reviewed and disclosed climate risks and opportunities closely related to its business, analyzed their potential financial impacts, and formulated corresponding management measures and action plans, so as to promote the continuous enhancement of the scientific management of climate issues and the transparency of information disclosure.

- **Governance**

The Group has formulated and implemented the *Governance System for Climate Change-related Issues – Terms of Reference*, formally integrating climate governance roles into the overall ESG governance framework, and clarifying the management requirements and division of responsibilities for climate-related work.



During the Reporting Period, Yunkang provided training on climate change matters to the Board of Directors and the management, aiming to enhance the skills and competencies of climate-related roles and comprehensively elevate Yunkang’s climate-related management level.

- **Strategy**

At the strategic level, Yunkang integrates climate risks and opportunities into its overall development strategy and business decisions. Combining the national “dual carbon” goals and industry trends, it assesses the potential impacts of material climate risks and opportunities on operating activities, conducts relevant financial impact assessments, and enhances its resilience and sustainable development capabilities in response to climate change.

- **Climate Risks and Opportunities**

In 2025, Yunkang reviewed and prioritized the climate risks and opportunities identified in the previous Reporting Period based on two dimensions: “the impact of the risk/opportunity” and “the likelihood of the risk/opportunity occurring”, so as to determine the potential impacts of each climate risk and opportunity on the business and operations. The following details the types of climate risks/opportunities identified by Yunkang, the descriptions and potential impacts of the risks/opportunities, the time horizons, the risk levels, and the response measures taken.

Risk Type	Specific Risk	Risk Description and Impact	Time Horizon	Risk Level	Response Measures
Physical Risk					
Acute Physical Risks	Adverse impacts caused by frequent extreme weather events	<p>Extreme weather events such as natural disasters (such as floods, typhoons, etc.) may lead to:</p> <ol style="list-style-type: none"> (1) equipment and assets damage in the Company's offices, laboratories and other places of operation; (2) threat to the personal safety of employees and impacts on the normal operation of the business; (3) supply chain disruptions, and impacts on the supply of materials (e.g., laboratory reagents, consumables, and equipment, etc.). At the same time, the Company's (cold chain) logistics and transportation may be hindered, and the transportation efficiency and capacity may be reduced, which may affect the detection speed and quality of sample testing, and in turn affect the Company's revenue. 	Short term	Low	<ul style="list-style-type: none"> • Formulating comprehensive emergency plans and conducting internal preventive education for employees who may face risks • Establishing a tiered early warning system and paying close attention to natural disaster forecasts • In the event of extreme weather warnings, immediately notifying employees to ensure safety and conducting safety patrols, and making advance deployments for the Company's assets • Assessing inventory and arrival timeliness, and prioritizing the allocation of materials in the event of extreme weather; negotiating to outsource or communicating with clients for deferred processing in the event of material shortages
Chronic Physical Risks	Adverse impacts caused by long-term changes in global climate patterns	<p>The increase in average temperature may lead to:</p> <ol style="list-style-type: none"> (1) increased energy consumption at the Company's operation sites such as offices and laboratories, increased (cold chain) logistics and transportation costs of the Company, resulting in an increase in the overall operating costs of the enterprise; (2) impacts on employee health, reducing work efficiency; (3) hazards to the health of all mankind, leading to an increase in human diseases and an increased demand from clients for the Company's testing services, which in turn leads to an imbalance between laboratory capacity load and demand. 	<p>Medium term Long term</p>	Low	<ul style="list-style-type: none"> • Tracking and analyzing energy consumption trends, and formulating and implementing strict energy-saving measures to reduce energy consumption • Paying attention to employee health, providing high-temperature subsidies and heat-relief measures for employees, and avoiding outdoor work for employees in high temperatures as much as possible • Tracking changes in testing service demands, making timely adjustments and deployments, and continuously improving testing efficiency • Taking adverse factors such as high temperatures into consideration in (cold chain) logistics and transportation, and formulating measures (including temperature node monitoring and early warning, timely temperature control management of samples by sample receiving personnel, and simultaneously increasing self-operated routes to shorten sample transit time) to reduce the impact of high temperatures • Investing in renewable energy (such as rooftop photovoltaics) to fundamentally reduce the carbon footprint of operations and the risk of future energy cost fluctuations

Risk Type	Specific Risk	Risk Description and Impact	Time Horizon	Risk Level	Response Measures
Transition Risks					
Policy and Legal Risks	Pricing on GHG Emissions	Global GHG emission policies and regulatory measures are constantly changing, and the Chinese mainland has also launched a carbon trading market. Even though Yunkang Group is currently not affected by the cap-and-trade scheme, future policy requirements related to carbon regulation and carbon pricing for the medical testing industry may directly or indirectly lead to an increase in operating costs.	Medium term Long term	Low	<ul style="list-style-type: none"> Establishing a carbon emission management system, committing to continuously reducing GHG emissions, and mitigating the impacts of carbon regulation and carbon pricing Tracking and grasping the policy trends of domestic and international carbon markets, and keeping abreast of policy directions in a timely manner Adopting advanced medical testing equipment and processes to improve energy efficiency and reduce energy consumption and carbon emissions During the Reporting Period, Yunkang carried out data collection and accounting work for major categories of Scope 3 carbon emissions
	Exposure to legal proceedings	Under stricter environmental laws and regulations, if the Company fails to meet relevant legal and regulatory requirements, it may face the risk of litigation. Fines and judgments brought by litigation may lead to negative impacts such as business losses and damage to brand and reputation, which in turn result in increased operating costs.	Medium term Long term	Very Low	<ul style="list-style-type: none"> Continuously paying attention to environmental laws and regulations of the state and the locations of operations, and strictly complying with relevant requirements Yunkang has obtained and continuously maintains the authoritative certification of the ISO 14001 environmental management system, managing related risks in a systematic and standardized manner, and establishing a solid compliance foundation
	Stricter disclosure requirements for Scope 1, Scope 2, and Scope 3 GHG emissions	To achieve the dual carbon goals, the Chinese mainland and Hong Kong Special Administrative Region governments, as well as relevant regulatory authorities, have increasingly stringent disclosure requirements for corporate Scope 1, Scope 2, and Scope 3 greenhouse gas emissions, which may lead to an increase in corporate compliance costs.	Short term Medium term	Low	<ul style="list-style-type: none"> Promptly following up on the latest GHG emission regulatory requirements. In 2025, Yunkang Group established a Scope 3 GHG accounting system, identified and quantified relevant Scope 3 emission categories, providing data support for the subsequent formulation of climate targets. Improving energy efficiency and actively researching the carbon trading market Enhancing internal awareness and capabilities regarding carbon emission management and disclosure through training and capacity building

Risk Type	Specific Risk	Risk Description and Impact	Time Horizon	Risk Level	Response Measures
Technology Risks	Expenditures of the transition to low-carbon technologies	Against the backdrop of global climate change, enterprises need to transition to low-carbon operations, including researching and developing new technologies (such as digital information technology) and switching to new energy/energy-saving equipment to replace traditional/high-energy-consuming and outdated equipment, all of which may lead to an increase in operating costs.	Medium term Long term	Low	<ul style="list-style-type: none"> • Launching ten major digitalized “cloud” systems and utilizing big data to achieve digitalized operations • Accelerating the pace of adopting new energy vehicles for the logistics fleet • Promoting paperless offices
Market Risks	Changes in customer behaviors	An increasing number of customers tend to use environmentally friendly products and services. Enterprises need to invest more costs to improve the energy use efficiency of their own products and services, so as to avoid reducing corporate competitiveness and affecting revenue due to failure to meet market demands.	Medium term	Very Low	<ul style="list-style-type: none"> • Maintaining close communication with customers to understand their needs in a timely manner • Actively adopting energy conservation and emission reduction measures, continuously improving the energy use efficiency of our products and services, and reducing GHG emissions • Leveraging ESG and green practices to enhance brand image and increase customer loyalty and investor confidence
Reputational Risks	Stakeholders’ growing concern over negative feedback	Society is increasingly concerned about climate change-related issues. If negative information emerges regarding climate change matters concerning the Company and its suppliers, it will affect the corporate reputation.	Medium term Long term	High	<ul style="list-style-type: none"> • Formulating emergency plans, establishing a crisis management team, and responding rapidly to negative information • Regularly publishing ESG reports, shaping a positive image, and enhancing trust • Maintaining communication with various stakeholders, responding to concerns in a timely manner, and sharing progress • Monitoring negative reports on the Company and its suppliers regarding climate change matters • If negative information regarding climate change matters emerges concerning a supplier, the Company will assess the risks associated with such negative information and take measures based on the assessment results • Participating in authoritative ESG ratings, continuously improving the quality of information disclosure and sustainable development performance, and enhancing the Company’s credibility and market recognition

Opportunity Type	Opportunity Description and Impact	Time Horizon	Action Plan
Resource Efficiency	By applying resource (energy and water resources) conservation measures, the enterprise can thereby improve resource use efficiency, reduce energy and water consumption, and consequently lower operating costs.	Long term	<ul style="list-style-type: none"> Promoting paperless offices, with printing costs decreasing by approximately RMB27,000 compared to 2024 Reducing the use of disposable items, and promoting green offices and reuse.
Energy Sources	By adopting low-emission energy sources, such as procuring more cost-effective “green” reagents, consumables, and equipment to reduce operating costs and the enterprise’s greenhouse gas emissions, the enterprise can thereby lower the compliance risks potentially brought by greenhouse gas emissions.	Medium term	<ul style="list-style-type: none"> Procuring high-efficiency machinery and lighting equipment with energy efficiency certifications or smart energy-saving functions Replacing traditional microscope mercury lamp light sources with LED light sources to reduce energy consumption and maintenance costs. Utilizing the atrium photovoltaic canopy to collect solar energy and convert it into electrical power for laboratory operations
Products and Services	Against the backdrop of the global transition towards low carbon, the enterprise can expand its service scope and enhance market competitiveness by developing climate-adaptive medical services, such as low-carbon medical testing services and remote medical testing services.	Medium term Long term	<ul style="list-style-type: none"> Yunkang actively responds to the global low-carbon transition trend, promotes the development of low-carbon medical and remote medical testing services, and reduces carbon emissions through innovative diagnostic models
Market	The environmental impacts caused by climate change may lead people to pay more attention to health issues, increasing the demand for medical testing services. If the enterprise can seize new opportunities and positive factors in the market, this may bring more clients and business opportunities.	Medium term Long term	<ul style="list-style-type: none"> Driven by the “Cloud System” as the core, it deepens digital applications and builds a one-stop smart medical diagnosis solution covering multiple business areas such as laboratory operations, customer service, and sales management, to meet diversified health testing needs Building a Remote Pathology Consultation Platform, utilizing AI smart diagnosis and cloud network technologies, improving per capita work efficiency by 100%, and enhancing market competitiveness
Adaptability	By continuously improving the capacity to respond to climate change and enhancing the reliability of the overall supply chain and operational capacity under different conditions, the enterprise and its supply chain can improve climate resilience, thereby increasing operational efficiency and reducing operational risks.	Medium term Long term	<ul style="list-style-type: none"> Through multi-party synergy at the governance, environmental, and social levels, strengthening climate risk and supply chain management from institutional, procurement, training, and data management aspects, to continuously improve the stability and adaptability of the supply system

Financial Impact Analysis

On the basis of identifying climate risks and opportunities, Yunkang further conducted a climate-related financial impact assessment to analyze the potential impacts of climate risks and opportunities on the Group's asset value, operating costs, revenue structure, and overall financial performance, providing a solid reference for the management to comprehensively understand the relevant impacts and make prudent decisions.

Material Climate Risks/Opportunities		Financial Impact
Acute Physical Risks	Adverse impacts caused by frequent extreme weather events	<ul style="list-style-type: none"> Asset Impairment: Damage to equipment and assets at operation sites leading to the impairment of corporate assets Increase in Costs: Repairing or replacing damaged equipment and assets may increase operating costs Decrease in Revenue: The testing speed and quality of testing samples being affected may reduce corporate revenue. The inability of the business to operate normally may also reduce corporate revenue
Chronic Physical Risks	Adverse impacts caused by long-term changes in global climate patterns	<ul style="list-style-type: none"> Increase in Costs: Increased energy consumption at operation sites, thereby increasing energy expenses and costs; rising temperatures leading to a need for more cold chain transportation to maintain product quality, thereby increasing logistics costs; the Company needing to increase the number of laboratories and expand capacity to meet increased testing demands, thereby increasing operating costs Decrease in Revenue: A decline in employee work efficiency may lead to a decrease in the overall operational efficiency of the Company, thereby reducing corporate revenue
Policy and Legal Risks	Pricing on GHG Emissions	<ul style="list-style-type: none"> Increase in Costs: The Company needs to invest more resources and funds to comply with carbon emission policies and regulatory requirements, including taking emission reduction measures and purchasing carbon emission allowances, thereby increasing operating costs
	Stricter disclosure requirements for Scope 1, Scope 2, and Scope 3 GHG emissions	<ul style="list-style-type: none"> Increase in Costs: The Company needs to invest more resources and funds to monitor and report GHG emissions and ensure relevant disclosure compliance, thereby increasing compliance costs
	Exposure to legal proceedings	<ul style="list-style-type: none"> Increase in Liabilities: Fines and legal fees brought by litigation may increase the liabilities of the Company Increase in Costs: The Company needs to invest additional resources and funds to meet laws and regulatory requirements, thereby increasing compliance costs

Material Climate Risks/Opportunities		Financial Impact
Technology Risks	Expenditures of the transition to low-carbon technologies	<ul style="list-style-type: none"> Asset Impairment: Replacing outdated equipment and transitioning to low carbon may lead to the impairment of old equipment and assets Increase in Costs: Investing in new technology research and development and updating equipment may increase corporate investment and operating costs
Market Risks	Changes in customer behaviors	<ul style="list-style-type: none"> Decrease in Revenue: If the Company fails to timely meet the market demand for environmentally friendly products and services, it may lead to customer attrition, thereby resulting in a decrease in revenue
Reputation Risks	Stakeholders' growing concern over negative feedback	<ul style="list-style-type: none"> Decrease in Revenue: Damage to the Company's reputation may lead to customer attrition or a decline in market share, thereby resulting in a decrease in revenue Financing Difficulties: Damage to the Company's reputation may lead to increased difficulty in financing and increased financing costs, exerting a negative impact on the Company's capital structure and financing activities
Climate Opportunities	Resource Efficiency	<ul style="list-style-type: none"> Decrease in Costs: Reduced energy and water resource consumption of the Company leads to lower operating costs, such as electricity and water expenses
	Energy Sources	<ul style="list-style-type: none"> Decrease in Costs: Procuring more cost-effective "green" reagents, consumables, and equipment can improve energy efficiency, reduce energy consumption, and lower operating costs. A reduction in greenhouse gas emissions of the Company can minimize compliance risks, such as fines and litigation resulting from violations of environmental regulations
	Products and Services	<ul style="list-style-type: none"> Increase in Revenue: Developing and upgrading climate adaptation-related medical services (e.g., remote medical testing services) helps expand the Company's service scope and cover a broader customer base, hence increasing revenue
	Market	<ul style="list-style-type: none"> Increase in Revenue: Increased customers and business opportunities lead to revenue increase of the Company
	Adaptability	<ul style="list-style-type: none"> Decrease in Costs: Increasing climate resilience can help the Company reduce operational risks and decrease unexpected costs associated with climate change, such as disaster recovery costs, thereby lowering operating expenses

Risk Management

Yunkang has integrated climate-related matters into its overall operational risk assessment and management system, established a standardized climate risk and opportunity management process, and continuously carried out the identification, assessment, and control of climate risks and opportunities. During the Reporting Period, the Group systematically conducted a review of climate-related risks and opportunities, and on this basis, further analyzed their potential financial impacts.

Process for the Review of Climate Risks and Opportunities, Financial Impact Analysis, and Scenario Analysis

1 List of Climate Risks and Opportunities

Based on the list of climate risks and opportunities from the previous reporting period, with reference to industry disclosure practices, research materials, and the policy environment, and in combination with the characteristics of its own value chain and operating regions, Yunkang established the 2025 list of climate risks and opportunities.

2 Review of Climate Risks and Opportunities

Prioritizing various climate risks and opportunities from key dimensions such as the degree of impact and the likelihood of occurrence, and combining the professional judgment of the internal management to form a climate risk and opportunity matrix.

3 Qualitative Financial Impact Analysis

Evaluating and analyzing the impacts of various climate risks on Yunkang's business model and value chain, and conducting a qualitative financial impact analysis.

4 Response Measures and Continuous Improvement

Reviewing and evaluating existing management measures, formulating and optimizing response action plans in conjunction with industry best practices, and continuously enhancing climate risk management capabilities and business resilience.

Metrics and Targets

To further strengthen the management of GHG emission data, Yunkang has established a Scope 3 GHG accounting system and, in accordance with the *Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standard*, is systematically advancing the identification and calculation of Scope 3 emissions. Through a cross-departmental collaboration mechanism, on the basis of the identified Scope 3 emission categories relevant to business operations, the Group has continuously improved the collection, collation, and analysis processes of GHG emission data, providing a reliable basis for subsequent carbon management and emission reduction decisions.

GHG Scope 3 Categories Relevant to the Group's Business Operations

Category 1: Purchased Goods and Services

Category 2: Capital Goods

Category 4: Upstream Transportation and Distribution

Category 5: Waste Generated in Operations

Category 6: Business Travel

Category 7: Employee Commuting

Category 8: Upstream Leased Assets

Category 9: Downstream Transportation and Distribution

Yunkang is committed to reducing GHG emissions, monitoring and disclosing the GHG emissions generated by the Company's operations on an annual basis, and continuously strengthening relevant management. During the Reporting Period, the Company's GHG emissions are as follows:

GHG	Unit	Data in 2025
Total GHG Emissions	tCO ₂ e	9,611.57
Intensity of GHG emission	tCO ₂ e/million RMB	15.99
GHG emissions (Scope 1)	tCO ₂ e	1.19
GHG emissions (Scope 2)	tCO ₂ e	2,548.76
GHG emissions (Scope 3)	tCO ₂ e	7,061.61

SOCIAL AND INCLUSION

8

Share Prosperity For All Through People-Centric Development

9

Care For The Community With Benevolence



8 SHARE PROSPERITY FOR ALL THROUGH PEOPLE-CENTRIC DEVELOPMENT

Yunkang adheres to a people-oriented approach, regards talent as the core driving force and asset of the enterprise's development, and always strictly abides by the protection of employee rights and interests. It is committed to creating a fair, just, caring, inclusive, and dynamic workplace environment, effectively enhancing employees' sense of belonging and value. Through a comprehensive training and development system, diverse career paths, and all-round welfare protection, it pays attention to the physical and mental health and career growth of employees, working hand in hand with them to build a better future of sustainable development.

8.1 PROTECTING EMPLOYEE RIGHTS

8.1.1 Employment Management and Diversity and Inclusion

Yunkang strictly complies with laws and regulations such as the *Labor Law of the People's Republic of China* 《中華人民共和國勞動法》, the *Civil Code of the People's Republic of China* 《中華人民共和國民法典》, and the *Provisions on the Prohibition of the Use of Child Labor* 《禁止使用童工規定》. It has also formulated the *Yunkang Group Employee Handbook* (《雲康集團員工手冊》), the *Attendance and Leave Management Measures of Yunkang Group* 《雲康集團考勤與休假管理辦法》, and the *Detailed Attendance Rules of Yunkang Group* 《雲康集團考勤細則》. The Company strictly implements various internal management systems, covering employee remuneration, dismissal, recruitment, promotion, working hours, leave, equal opportunities, diversity and inclusion, anti-discrimination, and various employee benefits. It has also established a sound mechanism to strictly prohibit the employment of child labor and forced labor.

Yunkang has established a standardized talent recruitment and management system, formulated and strictly implemented the *Yunkang Recruitment Management Measures* 《雲康招聘管理辦法》, and built an efficient and standardized recruitment process. Upholding the principles of "openness, fairness, competition, merit-based selection, and matching of talents and posts", the Company introduces outstanding talents through diverse channels such as online recruitment, campus recruitment, and internal referrals. Candidates are required to go through standardized procedures including resume screening, professional interviews, and remuneration negotiations, and ultimately candidates best suited for the positions are hired. The Company has established a comprehensive labor management plan. The salary levels of the Group and its subsidiaries are implemented in accordance with the relevant regulatory standards of their respective provinces and municipalities, ensuring that they are not lower than the local minimum wage and basic living standards.


The Company adheres to the philosophy of equal employment, maintains a zero-tolerance policy against any form of discriminatory behavior, and eliminates discrimination based on race, religion, skin color, age, gender, nationality, and marital status throughout the entire process of recruitment, employment, remuneration, and promotion. At the same time, it strictly implements the principle of equal pay for equal work, ensuring that male and female employees in the same position have consistent remuneration standards, and is committed to building a fair, just, open, and inclusive workplace environment, effectively safeguarding the legitimate rights and interests of employees.

Yunkang attaches great importance to the protection of employees' human rights, firmly puts an end to child labor and forced labor, strictly implements identity verification and age validation during the onboarding process, and prevents illegal employment from the source. It maintains a zero-tolerance policy against violations such as forced labor and child labor. Upon discovery, it will immediately initiate an investigation, strictly hold the responsible parties accountable, and take remedial measures in accordance with the law. During the Reporting Period, the Company did not experience any illegal or non-compliant incidents involving child labor or forced labor.

The Company lawfully implements a standard working hour system of five days and eight hours. It has standardized overtime management in accordance with the *Attendance and Leave Management Measures of Yunkang Group* 《雲康集團考勤與休假管理辦法》 and the *Detailed Attendance Rules of Yunkang Group* 《雲康集團考勤細則》, and arranges compensatory leave or pays overtime compensation. These measures effectively safeguard the legitimate rights and interests of employees. At the same time, the Company implements various leave rights such as statutory holidays, maternity leave, marriage leave, and annual leave in accordance with national regulations, effectively safeguarding employees' right to rest. The Company strictly adheres to the requirements of relevant laws and regulations. When implementing personnel optimization adjustments or large-scale layoffs, it lawfully fulfills its obligations of consultation and notification, safeguarding the legitimate rights and interests of employees.

As of December 31, 2025, the Company had a total of 1,064 employees, comprising 1,047 full-time employees and 17 part-time employees. Employees aged under 30 accounted for 39.47% of the Company, while female employees accounted for 57.24%. Females accounted for 35.42% of management-level employees and 19.44% of senior executives, fully reflecting Yunkang's commitment to building a gender-equal, young, and dynamic workplace. At the same time, 92.39% of the Company's employees are of Han ethnicity, and 7.61% are of ethnic minorities, further promoting workplace diversity.


The number of employees categorized by gender, job rank, age, region, ethnicity, and educational background is as follows:



8.1.2 Employee Benefits and Care Protection

Yunkang is committed to developing a sound employee benefits system. On the basis of legally paying pension insurance, medical insurance, unemployment insurance, work-related injury insurance, maternity insurance and the housing provident fund, the Company provides additional benefits such as commercial insurance, annual health check-ups and high-temperature subsidies, so as to fully safeguard employees' rights and interests. The Company attaches great importance to the care and rights protection of female employees, and organizes diverse activities and training services such as tea art, etiquette, yoga, and psychological counseling through the labor union, focusing on the physical and mental health of employees. At the same time, taking into account actual operational needs, the Company allows employees to apply for remote working arrangements under specific circumstances, continuously optimizing the employee experience and effectively enhancing employees' sense of happiness and belonging.

Yunkang Welfare System



Employee Activities

At the same time, in response to the needs of different employee groups, the Company carries out a rich and diverse range of care and cultural activities: regularly sending work anniversary wishes to employees and holding quarterly birthday parties to strengthen a sense of ritual and belonging; carrying out the "New Year" activity during the Spring Festival to create a joyful and peaceful festive atmosphere; holding themed events on International Women's Day to pay tribute to the contributions of female employees and promote the construction of an inclusive workplace; and launching the "Spiritual Ark" corporate reading activity to focus on the spiritual growth and inner fulfillment of employees. Through a series of activities combining warmth and quality, the Company continuously fosters harmonious and positive employee relations, and constantly enhances team cohesion and employees' sense of belonging.



Birthday Party Activity



Women's Day Activity



Emotional Release Station



Mental Health Activity



Spring Festival Activity

8.1.3 Employee Communication and Feedback

Yunkang attaches great importance to employee communication and the protection of employee rights and interests. It has formulated the *Yunkang Employee Internal Communication/Complaint Management Measures* 《雲康員工內部溝通／申訴管理辦法》 to safeguard channels for employee expression and proactively listen to the voices and demands of employees. The Company has built a multi-dimensional communication platform, covering the “Hall of Honor” and “Employees’ Emotional Release Station” in the OA system, as well as a dedicated communication email: lossemotion@yunkanghealth.com, providing employees with channels for feedback, emotional expression, and stress relief. At the same time, combined with interactive activities such as reading clubs, it strengthens emotional communication and spiritual care to build an open, inclusive, and efficient internal communication system.


In 2025, the Company’s employee satisfaction rate reached 100%, fully reflecting employees’ high recognition of Yunkang in terms of job satisfaction, career motivation, career happiness, and work stress management.

8.2 CARING FOR EMPLOYEE HEALTH

Adhering to the “safety first” philosophy, Yunkang strictly complies with national and local laws and regulations such as the *Law of the People’s Republic of China on the Prevention and Control of Occupational Diseases* (《中華人民共和國職業病防治法》), the *Work Safety Law of the People’s Republic of China* (《中華人民共和國安全生產法》) and the *Fire Protection Law of the People’s Republic of China* (《中華人民共和國消防法》). To strengthen occupational health and safety management, the Company has formulated and implemented systems such as the *Production Safety Hazard Inspection Mechanism of Yunkang Group* (《雲康集團安全生產隱患檢驗機制》) and the *Environmental and Occupational Health and Safety Management Handbook* (《環境職業健康安全管理手冊》). The relevant provisions are applicable to all businesses and employees of the Group.

8.2.1 Occupational Health and Safety Management System

The Company compiles safety production management ledgers annually, regularly monitors occupational hazard factors, and has passed the ISO 45001 Occupational Health and Safety Management System Certification, continuously ensuring its stable operation, optimization, and improvement. At the same time, the Company has set clear occupational health and safety targets, striving to achieve “four zeros” in fire accidents, accidental injury accidents, hazardous chemical storage and use accidents, and pathogen infection accidents. In 2025, all occupational health and safety targets were achieved as scheduled, and no fatal work-related accidents have occurred in the past three years.



Occupational Health and Safety Management System Certificate

Work-related injuries and fatalities in 2025

0 case

Major safety liability accidents in 2025

0 case

8.2.2 Occupational Health and Safety Protection Measures

Taking the occupational health and safety of employees as the core, Yunkang covers areas such as biosafety, logistics safety, and fire safety. It builds a solid defense line against risks through institutional development, daily control, emergency drills, and employee care. The specific management measures are as follows:

Category	Main Management Measures
Biosafety	<ul style="list-style-type: none"> Establishing a biosafety management system, formulating the <i>Biosafety Manual</i> 《(生物安全手冊)》 and the <i>Occupational Exposure Emergency Plan</i> 《職業暴露應急預案》; strictly regulating personal protection, disinfection and sterilization, and hand hygiene; requiring all laboratory personnel to participate in emergency drills and training annually to reduce the risk of occupational exposure. Yunkang has defined clear safety targets to ensure zero violations and zero safety accidents. In 2025, the Company successfully achieved all biosafety-related targets, with both the completion rate and pass rate of special training reaching 100%; realizing the targets of zero biosafety accidents and zero violations.
Logistics Safety	<ul style="list-style-type: none"> Improving the logistics safety management system, formulating the <i>Operation Procedures for Emergency Response in Logistics Centers</i> 《物流中心應急處理操作規程》, and establishing an emergency management team; strengthening vehicle inspections and hidden danger rectifications, enhancing safety education and assessments for drivers, eliminating fatigue driving, and ensuring safety throughout the transportation process.
Fire Safety	<ul style="list-style-type: none"> Strictly implementing fire safety management systems and equipping professional fire-fighting equipment; executing daily patrols, monthly hidden danger investigations, and equipment testing; regularly conducting fire drills and training to enhance employees' emergency response capabilities and fire safety awareness.

The Company not only values the occupational health and safety management of its internal operations but also incorporates relevant standards into its procurement processes and contract specifications. When procuring renovation services, it requires suppliers to comply with construction quality, safe operation, and fire safety specifications to ensure supply chain quality and safety and reduce social risks; when procuring hazardous chemicals, it requires suppliers to possess corresponding qualifications, ensuring that transport vehicles, practitioners, and storage and transportation methods all comply with regulatory requirements, comprehensively safeguarding supply chain safety management.

8.3 EMPOWERING EMPLOYEE GROWTH

8.3.1 Incentive Mechanisms and Promotion

Yunkang has established a standardized and systematic performance management and talent promotion mechanism. Adhering to a performance-oriented and development-centric approach, the Company designs differentiated incentive models for different job attributes, and builds a dual-track career development system for both professional and managerial tracks. This fully unleashes employee potential and organizational vitality, providing solid talent support for the high-quality development of the enterprise.

Module	Core Content
Performance Management	<p>Formulating the <i>Yunkang Group Performance Management Method</i> 《雲康集團績效管理辦法》, and utilizing diversified performance tools to ensure clear orientation and efficient execution of performance management.</p> <ul style="list-style-type: none"> • Remuneration Mechanism: Determining the remuneration level based on job requirements, personal capabilities, and work performance, and implementing flexible incentives. • Professional and Technical Talents: Adopting a compensation model dominated by fixed salaries and supplemented by variable performance pay to reflect professional value. • Frontline Sales Team: Taking sales volume, payment collection rate, revenue contribution rate, and team building as core indicators, and utilizing the “Climbing Theory” to stimulate potential. • Evaluation Method: Taking into account both individual goals and team performance, conducting monthly, quarterly, and annual evaluations, and following up continuously through regular meetings, reports, and on-site communication to coach and improve employees’ capabilities.
Promotion and Evaluation	<p>Formulating the <i>Yunkang Business Cadre Promotion and Evaluation Management Method</i> 《雲康業務幹部晉升及評價管理辦法》 to establish a scientific and fair promotion and evaluation system.</p> <ul style="list-style-type: none"> • Assessment Dimensions: Covering five major dimensions: cultural identity, customer awareness, business thinking, teamwork, and work effectiveness. • Evaluation Method: Organized by the Human Resources Center, it implements multi-level assessments involving leaders in charge, direct superiors, peers, and subordinates to ensure comprehensiveness and fairness.

Module **Core Content**

Career Development Path


According to the *Yunkang Group Rank System Management Measures* 《雲康集團職級體系管理辦法》, the Company has built a dual-channel development path for both professional and managerial tracks.

- Professional Channel: Supporting technical talents to deepen their cultivation in professional fields and achieve the enhancement of professional value.
- Managerial Channel: Providing a development platform for employees with leadership potential, driving the team to create higher value.

Through the construction of the dual channels, promoting the coordinated development of professional and managerial capabilities, and building a diversified talent reserve system.

Internal Referral and Incentives

Formulating the *Yunkang Internal Referral Management Measures* 《雲康內部推薦管理辦法》 to clarify internal referral reward standards for different job categories, mobilizing employees' enthusiasm for referrals, broadening talent acquisition channels, and improving recruitment efficiency and quality; establishing a Restricted Share Unit Plan to recognize and incentivize employees who have contributed to the growth and development of the Company in the form of company share rewards, realizing the common growth of the enterprise and its employees.




Dual-Track Career Progression at Yunkang

8.3.2 Employee Training and Development

Yunkang attaches great importance to the growth and development of employees and has established a comprehensive and diversified training system. By formulating the *Staff Training and Assessment Management Operating Procedures of Yunkang* (《雲康員工培訓與考核管理操作規程》), based on the common development needs of the enterprise and its employees, it comprehensively enhances the comprehensive qualities of employees. For new employees, in accordance with the *Yunkang Group New Employee Training Management Measures* (《雲康集團新員工培訓管理辦法》), the Company provides online general onboarding training and offline on-the-job training to help them quickly integrate into the enterprise and become familiar with their positions. At the same time, it encourages employees to participate in job-related social training, lectures, and academic conferences. It also supports employees in obtaining professional qualification certificates in accordance with the *Yunkang Group Technical Title Management Measures* to enhance their professional capabilities. For employees' active learning behaviors, the Company provides financial rewards and reimburses relevant registration fees and travel expenses for external training, comprehensively assisting employees in achieving career development. In 2025, Yunkang's investment in employee training amounted to RMB466,800, averaging RMB400 in per capita training investment. The training hours for employees totaled 11,809 hours, averaging 13.25 hours for each employee.

Yunkang's employee training system focuses on "enterprise culture construction", "learning platform construction", "course system construction" and "key position capacity construction". Surrounding these four major directions, it provides employees with rich and diversified training programs, comprehensively facilitating the career growth and development of employees.



Certificate of Training Management System

Yunkang training system construction

Yunkang continuously advances corporate culture development, improves the content system of the "Fu Yun" training platform, optimizes course settings and knowledge accumulation, and carries out special capability and management capability training for key positions, comprehensively enhancing the comprehensive capabilities of employees.

• Enterprise culture construction

Yunkang coheres the minds of its people with culture and anchors its soul with systems. It has formulated the *Basic Principles of Yunkang’s Career Development* 《雲康事業發展的基本原則》 to institutionalize its core concepts, forge a consensus on values among all employees through publicity and education, and strengthen a contribution-oriented approach. In 2025, centering on the marketing line and the technical line, the Company advanced the talent echelon construction for key positions, deepened the standardization of three-level qualification requirements, quantified the values of “professionalism” and “excellence” into job requirements, and promoted the implementation of the concepts of “continuous improvement” and “efficient collaboration” through lean production management training.

• Learning platform construction

Yunkang deeply cultivates the building of a learning organization, advocates for employees to continuously learn and improve themselves, relies on the “Fu Yun” learning platform to broaden training forms, and provides employees with flexible and convenient online learning support. During the Reporting Period in 2025, the platform continuously empowered employees in various positions. The rich learning resources and convenient training forms effectively enhanced employees’ enthusiasm for participation and training effectiveness. This not only strengthened the professional skills and comprehensive literacy of employees but also cultivated high-quality talents for the Company, laying a solid talent foundation for Yunkang’s continuous innovation and high-quality development in the medical and healthcare field.



- **Course system construction**

In response to the business needs of the marketing line, the laboratory technical line, and the functional line, Yunkang has built three core course systems to provide employees with all-around professional support, so as to stimulate employees' potential.

Marketing line	During the Reporting Period, for the marketing line, the Company carried out special training and drills such as marketing management skills, the Six Steps of Professional Client Visits, marketing case sharing, and product promotion volume scaling. It independently developed 28 internal courses covering areas such as management role cognition, team management, business coaching, visit skills, and product knowledge. Through the mentor certification for the <i>Six Steps of Professional Visits</i> 《專業拜訪六步曲》, two standard courseware and 15 high-quality course materials were launched, enabling 90% of city managers and regional heads to fully master professional customer visiting skills, and promoting the standardization of marketing skills and the unification of work rhythms.
Laboratory technology line	Focusing on professional competency improvement, Yunkang developed 19 specialized laboratory testing courses during the Reporting Period, covering multiple core areas, including 1 clinical testing course, 6 pathology courses, 1 quality management course, and 1 lean operation course, to help employees continuously improve their professional capabilities and promote the continuous enhancement of the laboratory testing level.
Functional line	During the Reporting Period, various functional departments actively carried out on-the-job training, jointly developing and launching 17 courses on sample submission compliance, financial reimbursement, business travel, logistics operation specifications, biosafety, and emergency handling.
External courses	During the Reporting Period, 86 courses on public hospital operation management and 95 professional courses for financial positions were introduced.

- **Key position capacity construction**

Based on the business needs of various positions, Yunkang provides employees with targeted training such as professional lectures and courses, precisely cultivating talents for key positions. The Company also encourages independent learning and self-improvement, helping employees strengthen professional competencies and achieve steady career progress.

Laboratory technology line

In 2025, Yunkang continuously advanced the professional capability certification of laboratory technical talents. A total of 200 employees from the Guangzhou Clinical Testing Technology Center and the Precision Medicine Center completed the online courses of the learning map and passed the practical tasks. In accordance with the three-level capability certification standards and capability models of the laboratory technical line, 1 technical talent review meeting was organized to comprehensively evaluate 10 key backbones of technical management positions from six dimensions: professional skills, team growth contribution, business support, knowledge construction, comprehensive literacy, and personal achievements, thereby establishing a technical talent pool. In addition, in-service training on professional skills and quality control was carried out for laboratory professional positions. The professional departments and quality control departments of the three major laboratories respectively organized 167 professional skills training sessions and 8 quality training sessions, accumulating 195.5 hours of training with 3,100 person-times.

Marketing line

In 2025, Yunkang continuously strengthened its marketing talent cultivation system, built a three-level talent echelon covering client representatives, city managers, and regional heads, and launched a marketing echelon talent training camp. The Company carried out training through diversified methods such as personal development plan coaching, management courses, self-directed learning, and online assessments. It cumulatively held dozens of training activities throughout the year, with over 2,000 person-times, effectively enhancing the team's business mindset, market development capabilities, and overall performance.

International business reserve talents

In December 2025, the "Blue Ocean Expedition (藍海遠征)" international business talent empowerment project was officially launched. The course modules included thematic learning, laboratory technical observation, reading and sharing of *A Message to Garcia* 《把信送給加西亞》, and weekly English vocabulary self-study and self-testing. The thematic courses invited the Chairman of the Group and heads of various departments to give lectures, covering topics such as going-global strategy, market breakthrough, overseas finance, laboratory lean operations, quality systems, cross-business delivery, and supply chain resources. A total of 18 trainees participated in the project, accumulating 17.5 hours of training, conducting 4 reading club sharing sessions, and achieving a 90% pass rate in the English examination.

Digital transformation line

During the Year, the Information Center conducted special training on AI programming. Centering on modules such as large language model capabilities, AI programming development paths, basic principles, and practical tools, it systematically explained the applicable scenarios and collaboration methods of AI and handwritten codes, helping the team master the practical skills of AI-assisted development and improving programming development efficiency and quality. At the same time, focusing on the digital transformation plan, Yunkang trained employees to effectively utilize digital advancements, thereby improving efficiency and productivity and supporting the overall digital transformation goals of the organization.

9 CARE FOR THE COMMUNITY WITH BENEVOLENCE

Taking the role of a responsible corporate citizen as its own responsibility, closely adhering to the “proactive health” concept advocated by “Healthy China 2030”, and persisting in putting prevention first and serving the people, Yunkang actively fulfills its social responsibilities and sustainable development commitments, responding to social health needs with its professional service capabilities.

9.1 SAFEGUARDING PUBLIC HEALTH

Leveraging its advantages in professional testing and medical services, Yunkang extensively carries out public welfare initiatives such as health education, disease screening, and charitable clinical diagnostic activities and testing. By extending high-quality medical resources to the frontline of local communities, it effectively enhances public health awareness and protection levels, promoting the improvement of the public health system.

9.1.1 Popularizing Health Knowledge

In 2025, Yunkang conducted 65 lectures and events, covering special sessions on traditional Chinese medicine (TCM) therapy and health science popularization for primary and secondary school students by doctors. The lecture contents covered multiple aspects such as nutrition and health, growth and development, chronic disease management, TCM healthcare, emergency protection, and smoking control, reaching a cumulative audience of nearly 30,000 people. Through these efforts, it conveys scientific knowledge and elevates the level of public health awareness.

Health Knowledge Lectures

Month	Event Theme	Number of Participants
January	TCM Health Consultation Event	Over 200 persons
March	Science Popularization Consultation on Ending Tuberculosis	Over 200 persons
May	Universal Health • Diverse Protection	Over 500 persons
July	Eliminate Hepatitis, Inherit the National Essence	Over 200 persons
September	Silver Age Care • Cognitive Protection	Over 500 persons

9.1.2 Complimentary Screening and Free Consultations

Yunkang continuously drives the extension of complimentary medical services to the grassroots communities, leveraging its professional advantages to carry out various people-benefiting health initiatives. By delivering high-quality medical resources directly to community frontlines, the Company effectively improves public health protection capabilities.

Disease Screening

Yunkang continuously focuses on the life and health well-being of the public, actively promoting disease screening and early prevention and treatment.

In 2025, Yunkang joined hands with the medical institution alliances of Hainan Cancer Hospital to conduct screening for five major cancers: liver cancer, lung cancer, breast cancer, colorectal cancer, and gastric cancer, covering approximately 1,000 people. The Company strengthened early intervention and disease management, supporting the high-quality development of the public health system.



Complimentary Physical Examinations

With sincere, people-oriented public welfare practices, Yunkang actively gives back to society. Focusing on complimentary physical examinations, it fully leverages its professional advantages and practices the core philosophy of “respecting nature and loving others”.

In 2025, Yunkang Hainan held over 185 complimentary physical examination events, serving more than 22,036 person-times. At the same time, we carried out charitable clinical diagnostic activities, serving a cumulative total of over 10,900 person-times.



In 2025, Yunkang Zhuhai held over 132 complimentary physical examination events, serving more than 3,600 person-times. At the same time, we carried out charitable clinical diagnostic activities, serving a cumulative total of over 3,870 person-times.



Charitable Clinical Diagnostic Activities

Yunkang has successively entered communities to carry out a series of charitable clinical diagnostic activities, safeguarding residents' health with attentive services.

“National Basic Public Health Services for All”

The Company disseminates popular science knowledge of national basic public health services to safeguard residents' well-being. In the form of “science popularization + free consultation”, it provides free blood pressure and blood glucose measurements, establishes health records for residents, invites the elderly for physical examinations, and distributes health manuals. This helps residents understand their own health conditions and basic public health policies, effectively addressing their health consultation needs.



“Promoting Family Doctor Services”

Conducted in the form of “signing with family doctors”, it signs up residents for family doctors on-site, explains relevant policies, provides free blood pressure and blood glucose measurements, promotes basic public health services, and distributes health manuals, popularizing health knowledge and improving the quality of community grassroots health services.



9.1.3 Protecting Special Groups

Caring for the elderly and children and safeguarding the health of mothers and infants represent the original aspiration of public welfare services. Yunkang consistently places groups such as the elderly, pregnant and postpartum women, and children within its priority service vision, holding up a health protection umbrella for socially key groups through professional medical care and heartwarming actions.

Yunkang continuously advances disease prevention and control as well as medical treatment for the elderly, women, children, and infants, constantly improves the grassroots medical service guarantee system, and actively builds a public health prevention and control network



Focusing on Children's Health



Focusing on Students' Health

In 2025, Yunkang provided free health examination services for key groups such as children, students, and the elderly, focusing on health monitoring and disease prevention, and comprehensively elevating the health management level of key populations.

Caring for the mentally challenged group and supporting community rehabilitation, Yunkang fulfills its public welfare mission through concrete actions, holding up a warm protective umbrella for mental health partners



In 2025, the Beiguan Community Health Service Station deepened its involvement in the field of mental health public welfare, taking the Beiguan Runxin Service Station as the core position. It created a “medical-rehabilitation-community integration” model featuring “Western medicine as the foundation, TCM as the feature, and natural healing as the supplement”. Through measures such as targeted screening, personalized file building, the service quality and efficiency were continuously improved.

During the Year, it cumulatively served 200 mental health partners, 34% of whom returned to their jobs after conditioning and training, alleviating the burden on their families and society. It organized 60 rehabilitation activities with over 1,000 person-times, assisting mental health partners in reintegrating into society.

9.2 EMPOWERING PEOPLE'S LIVELIHOOD THROUGH PUBLIC WELFARE

Fulfilling the original aspiration through public welfare, and warming people's hearts through services. To steadily advance the construction of healthy communities and effectively solve the urgent difficulties and anxieties of the masses, we focus on livelihood needs, deeply cultivate the public welfare field, carry out multi-dimensional public welfare services, and deliver warmth through concrete actions.



Innovating "Idle Land + Public Welfare" to Create a New Benchmark in Livelihood Services

By breaking resource utilization barriers and innovating the public welfare mechanisms, Yunkang revitalizes idle resources, stimulates public welfare vitality, and creates a replicable and scalable livelihood service model.



Building Bridges of Love and Empowering Rural Revitalization

Focusing on the needs of the masses and special groups, Yunkang builds a bridge for assistance, driving the transformation of public welfare services from "blood-transfusion" style assistance to "blood-generation" style empowerment. The Company also establishes a caring platform for poverty alleviation and agricultural support, accurately connecting farmers with market demand, smoothing agricultural product sales channels, helping local households increase income, and spreading the warmth of social responsibility.





Caring Donations to Support Education, Lighting up the Hope of Rural Education

With continuous attention to rural education and the healthy growth of students, Yunkang supports high-quality rural education through caring donations. By leveraging public welfare power, the Company helps improve teaching efficiency and educational outcomes, lighting up the dreams and future of rural children.



10 APPENDIX 1: ESG KPIS

10.1 ENVIRONMENTAL KPIS

ESG indicators	Unit	Data in 2025	Data in 2024
A1.1 Air pollutant emissions¹			
Xylene	Tonnes	0.0001	0.00011
Phenols	Tonnes	0	0
TVOC ²	Tonnes	0	0
NOx	Tonnes	0.00079	0
SOx	Tonnes	0.00001	0
CO	Tonnes	0.02	0
PM 2.5	Tonnes	0.00014	0
PM 10	Tonnes	0.00014	0
A1.2 Direct and indirect GHG emission³			
GHG emission (scope 1) ⁴	tCO ₂ e	1.19	0
GHG emission (scope 2) ⁵	tCO ₂ e	2,548.76	3,267.44
GHG emission (scope 3) ⁶	tCO ₂ e	7,061.61	/
Total GHG emission ⁷	tCO ₂ e	9,611.57	3,267.44
Total density of GHG emission	tCO ₂ e/million RMB	15.99	4.59
A1.3 Discharge of hazardous waste⁸			
Waste tube	Tonnes	0	0
Waste toner cartridges and ink cartridges	Tonnes	0	0
Waste activated carbon	Tonnes	0.18	0
Sludge treatment at wastewater treatment station	Tonnes	0.64	0
Medical waste	Tonnes	180.78	250.02
Total hazardous waste discharge	Tonnes	181.59	250.02
Total discharge density of hazardous waste	Tonnes/million RMB	0.30	0.35
A1.4 Discharge of non-hazardous waste⁸			
Waste cartons	Tonnes	7.77	8.11
Office waste paper	Tonnes	6.00	19.00
Household waste	Tonnes	19.58	24.37
Waste plastic	Tonnes	1.22	1.45
Total non-hazardous waste discharge	Tonnes	34.57	52.92
Total discharge density of non-hazardous waste	Tonnes/million RMB	0.06	0.07
Waste carton recycled	Tonnes	7.17	8.11
Office waste paper recycled	Tonnes	5.94	6.94
Waste plastic recycled	Tonnes	1.22	1.45
Total non-hazardous waste recycled	Tonnes	14.33	16.49

ESG indicators	Unit	Data in 2025	Data in 2024
A2.1 Energy consumption			
Purchased electricity	Thousand kWh	4,803.55	6,089.16
Direct energy (gasoline) ⁹	Thousand kWh	4.28	0
Total energy consumption	Thousand kWh	4,807.83	6,089.16
Total energy consumption intensity	Thousand kWh/million RMB	8.00	8.55
A2.2 Water consumption			
Total water consumption ¹⁰	Cubic meter	8,600.20	17,111.26
Total water consumption intensity	Cubic meter/million RMB	14.31	24.03
Recycled water consumption	Cubic meter	0	0

Illustration for environmental KPIs:

The time of data collection covers the period from January 1, 2025 to December 31, 2025. The scope of environmental data collection covers the headquarters of the Group and 5 medical laboratories in Guangzhou, Chengdu, Hefei, Jinan and Shantou unless otherwise specified.

- Air pollutant emissions primarily arise from the use of volatile reagents and the operation of company-owned official vehicles. Air pollutants generated from the use of volatile reagents include xylene, phenols and TVOC; while those from the operation of company-owned vehicles include conventional air pollutants such as sulfur oxide, nitrogen oxides and particulate matter. Emissions of air pollutants from the use of volatile reagents are only accounted for at Guangzhou Da'an Clinical Laboratory, as emissions from other laboratories are negligible. The calculation of the above air pollutant emissions from the use of volatile reagents is mainly based on relevant monitoring reports of the Company;
- TVOC refers to the abbreviation of Total Volatile Organic Compounds;
- Total GHG emissions include direct GHG emissions and indirect GHG emissions; in particular, direct GHG emissions primarily come from the use of vehicle gasoline, and the emission coefficient mainly refers to the *Guidelines for Accounting and Reporting of Greenhouse Gas Emissions for Land Transportation Enterprises (Trial)*; indirect GHG emissions come from purchased electricity. The GHG emission coefficient of purchased electricity in 2025 is based on the 2023 national average carbon dioxide emission factor for electricity set out in the *Announcement on Issuing the 2023 Electric Power Carbon Dioxide Emission Factors* issued by the Ministry of Ecology and Environment of the People's Republic of China and the National Bureau of Statistics; the GHG emission coefficient of purchased electricity in 2024 is based on the 2022 national average carbon dioxide emission factor for electricity set out in the *Announcement on the Release of 2022 Electricity Carbon Dioxide Emission Factors* issued by the Ministry of Ecology and Environment of the People's Republic of China;
- GHG emissions (scope 1) are mainly generated from the use of gasoline by vehicles. In 2025, Guangzhou Da'an Clinical Laboratory added one company vehicle, resulting in corresponding Scope 1 GHG emissions;
- GHG emission (scope 2) primarily comes from purchased electricity. GHG emissions (scope 2) in 2025 also decreased accordingly due to a significant reduction in purchased electricity consumption as a result of the business adjustments by the Company;
- Yunkang collected and disclosed Scope 3 GHG emissions data for the first time in 2025. GHG emissions (Scope 3) are mainly derived from Categories 1, 2, 4, 5, 6, 7, 8 and 9. The calculation methods are based on the *U.S. Environmental Protection Agency (EPA) Supply Chain Greenhouse Gas Emission Factors (2022)*, the *Department for Environment, Food & Rural Affairs (DEFRA) Greenhouse Gas Emission Factors (2025)*, the *Emission Factors for Typical Business Travel and Accommodation Activities in China (2024)* by Zero-Carbon Laboratory, and the *Provincial Road Transport CO2 Emission Factors in China* by the Chinese Society for Environmental Sciences;
- In 2025, Yunkang included scope 3 GHG emissions in its accounting system for the first time, resulting in an increase in total GHG emissions and emission intensity. Accordingly, the relevant data are not comparable with those of previous years;
- According to the Company's business nature and actual operating conditions, hazardous waste includes waste lamp tubes, waste toner cartridges, waste activated carbon, sludge treatment at wastewater treatment station and medical waste; non-hazardous waste includes waste cartons, office waste paper, household waste and waste plastic;
- In 2025, Guangzhou Da'an Clinical Laboratory added one company vehicle, which resulted in corresponding gasoline consumption;
- Water resource consumption in 2025 decreased slightly compared with previous years due to business restructuring of the Company.

10.2 SOCIAL KPIS

ESG indicators		Unit	Data in 2025	Data in 2024
B1 Employment				
B1.1 Total workforce by gender, employment type, age group and geographical region				
	Total workforce	person	1,064	1,249
By gender	Male	person	455	652
	Female	person	609	858
By age group	Below age 30	person	420	762
	Age 30 to 50	person	605	708
	Above age 50	person	39	40
By rank	Total senior management	person	36	32
	Male senior management	person	29	25
	Female senior management	person	7	7
	Total middle management	person	108	162
	Male middle management	person	64	99
	Female middle management	person	44	63
	Total non-management	person	920	1,316
	Female non-management	person	558	788
By region	Total employees in China mainland	person	1,064	1,508
	East China	person	87	198
	South China	person	852	1,106
	Central China ¹	person	0	30
	Southwest China	person	125	174
	Total employees in Hong Kong, Macao, Taiwan and overseas regions	person	0	2
By employment type	Full-time	person	1,047	1,483
	Part-time	person	17	27
Total workforce by other categories				
By education	Master and above	person	61	61
	Bachelor and below	person	1,003	1,188
By ethnicity	Han	person	983	1,153
	Ethnic minorities	person	81	96

ESG indicators		Unit	Data in 2025	Data in 2024
Other employment data				
Number of researchers		person	89	109
Labor contract signing rate for full-time employees		%	100	100
Social insurance coverage rate for full-time employees		%	100	100
Labor union coverage rate for full-time employees		%	100	100
Proportion of female holding STEM ² -related positions		%	65	60
B1.2 Employee turnover rate by gender, employment type, age group and geographical region³				
Total turnover rate		%	27.82	35.31
By gender	Male	%	27.91	34.24
	Female	%	27.75	58.28
By age group	Below age 30	%	30.24	20.58
	Age 30 to 50	%	26.28	13.77
	Above age 50	%	25.64	0.96
By region	China mainland	%	27.82	35.15
	Hong Kong, Macao, Taiwan and overseas regions	%	/	0.16
By rank	Senior management	%	5.56	0.40
	Middle management	%	31.48	2.56
	Non-management	%	28.26	32.35
B2 Health and safety⁴				
B2.2 Lost days due to work injury				
Lost days due to work injury		day	251	112
B3 Development and training				
B3.1 Percentage of employees trained by gender and employee category⁵				
By gender	Male	%	43.66	48.76
	Female	%	56.34	51.24
By rank	Senior management	%	4.04	3.27
	Middle management	%	12.12	13.68
	Non-management	%	83.84	83.05

ESG indicators		Unit	Data in 2025	Data in 2024
Percentage of employees trained by other categories⁵				
By training content	Marketing line	%	18.07	19.82
	Laboratory technology line	%	47.81	49.45
	Functional line	%	34.12	30.72
By age	Below age 30	%	39.62	38.45
	Age 30 to 50	%	57.69	59.56
	Above age 50	%	2.69	1.98
By ethnicity	Han	%	92.14	91.87
	Ethnic minorities	%	7.86	8.13
B3.2 Average training hours completed per employee by gender and employee category⁶				
By gender	Male	hour	15.13	22.11
	Female	hour	11.80	16.42
By rank	Senior management	hour	23.61	23.06
	Middle management	hour	17.88	30.50
	Non-management	hour	12.09	17.18
Average training hours completed per employee by other categories⁶				
By training content	Marketing line	hour	24.54	45.51
	Laboratory technology line	hour	13.19	16.93
	Functional line	hour	7.37	5.87
By age	Below age 30	hour	11.41	17.46
	Age 30 to 50	hour	14.73	20.56
	Above age 50	hour	8.75	11.95
By ethnicity	Han	hour	13.34	19.36
	Ethnic minorities	hour	12.24	17.33

ESG indicators		Unit	Data in 2025	Data in 2024
B5 Supplier management				
B5.1 Number of suppliers by geographical region				
By region	Total suppliers in China mainland	unit	332	385
	North China	unit	17	25
	East China	unit	92	92
	South China	unit	186	203
	Central China	unit	21	32
	Northwest China	unit	0	1
	Southwest China	unit	15	31
	Northeast China	unit	1	1
B6 Product responsibility				
B6.2 Number of products and service related complaints received				
Number of complaints received		case	152	206
Number of customer complaints dealt with		case	152	206
B6.5 Consumer data protection and privacy				
Information security breaches or other major network security incidents		case	0	0
Approval rate of corporate information security risk assessments		%	100	100
Average hours of information security training per person		hour	9	8
Coverage rate of informing customers about privacy policies		%	100	100
Coverage rate of customers using data control services		%	100	100
Customer opt-in consent rate for privacy policy coverage		%	100	100
Customer coverage rate for information disclosure policies		%	100	100
Frequency of information system and data security audits		case/year	3	3
Employee coverage rate for information security and privacy protection training		%	100	100

ESG indicators	Unit	Data in 2025	Data in 2024	
B7 Anti-corruption				
B7.1 Number of concluded legal cases regarding corrupt practices and outcomes				
Number of concluded legal cases regarding corrupt practices	case	0	0	
B7.3 Anti-corruption training provided to directors and staff				
Number of participants trained	Directors	person	4	4
	Staff	person	276	96
Training hours	Directors	hour	8	12
	Staff	hour	414	221
B8 Community investment				
B8.2 Resources contributed to the focus area				
Complimentary medical examinations	case	317	237	
Charitable clinical diagnostic activities	case	245	240	
Health lectures	case	106	107	

Illustration for social KPIs:

1. In 2025, the number of employees in Central China decreased to zero due to business restructuring of the Company;
2. STEM refers to Science, Technology, Engineering and Mathematics;
3. The employee turnover rate is calculated based on: Turnover rate (per category) = Number of employees in the specified category leaving employment/Total number of employees;
4. Social KPIs cover all employees of Yunkang Group;
5. The percentage of employees trained is calculated based on: Percentage of employees trained = Number of employees in the specified category who took part in training/Total number of employees who took part in training;
6. The average training hours completed per employee is calculated based on: Average training hours completed per employee = Total number of training hours completed by employees in the specified category/Total number of employees in the specified category who took part in the training.

11 APPENDIX 2: INDEX OF ESG REPORTING CODE OF THE STOCK EXCHANGE

ESG indicators	Description of indicators	Chapters/Notes
A1 Emissions general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	7.1 Promoting green operations
A1.1	The types of emissions and respective emissions data.	10.1 Environmental KPIs
A1.2	Deleted on January 1, 2025.	10.1 Environmental KPIs
A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	10.1 Environmental KPIs
A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	10.1 Environmental KPIs
A1.5	Description of emission target(s) set and steps taken to achieve them.	7.1 Promoting green operations
A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	7.1 Promoting green operations

ESG indicators	Description of indicators	Chapters/Notes
A2 Use of resources general disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	9.1 Implementing green operations
A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	10.1 Environmental KPIs
A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	10.1 Environmental KPIs
A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	7.1 Promoting green operations
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	7.1 Promoting green operations
A2.5	Total packaging material used for finished products (in tonnes) and, if applicable with reference to per unit produced.	Not applicable. Yunkang is a non-production enterprise and does not involve packaging material used for finished products
A3 The environment and natural resources general disclosure	Policies on minimizing the issuer's significant impacts on the environment and natural resources.	7.1 Promoting green operations
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	7.1 Promoting green operations

ESG indicators	Description of indicators	Chapters/Notes
B1 Employment general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	8.1 Protecting employee rights In 2025, Yunkang experienced no incidents of discrimination or harassment.
B1.1	Total workforce by gender, employment type (for example, full-time or part-time), age group and geographical region.	10.2 Social KPIs
B1.2	Employee turnover rate by gender, age group and geographical region.	10.2 Social KPIs
B2 Health and safety general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	8.2 Caring for employee health
B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	8.2 Caring for employee health
B2.2	Lost days due to work injury.	10.2 Social KPIs
B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	8.2 Caring for employee health
B3 Development and training general disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	8.3 Empowering employee growth
B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	10.2 Social KPIs
B3.2	The average training hours completed per employee by gender and employee category.	10.2 Social KPIs
B4 Labor standards general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labor.	8.1 Protecting employee rights
B4.1	Description of measures to review employment practices to avoid child and forced labor.	8.1 Protecting employee rights
B4.2	Description of steps taken to eliminate such practices when discovered.	8.1 Protecting employee rights

ESG indicators	Description of indicators	Chapters/Notes
B5 Supply chain management general disclosure	Policies on managing environmental and social risks of the supply chain.	6.5 Deepening ecological synergy
B5.1	Number of suppliers by geographical region.	6.5 Deepening ecological synergy
B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	6.5 Deepening ecological synergy
B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	6.5 Deepening ecological synergy
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	6.5 Deepening ecological synergy
B6 Product responsibility general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	6.3 Improving innovation mechanisms 6.1 Dual-driven operations of quality and efficiency 6.2 Enhancing service quality
B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Not applicable. Yunkang is a non-production enterprise and does not involve products sold or shipped subject to recalls

ESG indicators	Description of indicators	Chapters/Notes
B6.2	Number of products and service related complaints received and how they are dealt with.	6.2 Enhancing service quality
B6.3	Description of practices relating to observing and protecting intellectual property rights.	6.3 Improving innovation mechanisms
B6.4	Description of quality assurance process and recall procedures.	6.1 Dual-driven operations of quality and efficiency
B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	6.2 Enhancing service quality
B7 Anti-corruption general disclosure	Information on the policies and compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	5.1 Corporate governance
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	10.2 Social KPIs
B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	5.1 Corporate governance
B7.3	Description of anti-corruption training provided to directors and staff.	10.2 Social KPIs
B8 Community investment general disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	9 Care for the community with benevolence
B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, sport).	9 Care for the community with benevolence
B8.2	Resources contributed (e.g. money or time) to the focus area.	10.2 Social KPIs

Part D: “Comply or explain” principle Climate-related disclosures		Chapters/Notes
(I) Governance		
19 (a) The governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities:		Governance
i) how the body(s) or individual(s) determines whether appropriate skills and competencies are available or will be developed to oversee strategies designed to respond to climate-related risks and opportunities;		Governance
ii) how and how often the body(s) or individual(s) is informed about climate-related risks and opportunities;		Governance
iii) how the body(s) or individual(s) takes into account climate-related risks and opportunities when overseeing the issuer’s strategy, its decisions on major transactions, and its risk management processes and related policies, including whether the body(s) or individual(s) has considered trade-offs associated with those risks and opportunities;		Governance
iv) how the body(s) or individual(s) oversees the setting of, and monitors progress towards, targets related to climate-related risks and opportunities (see paragraphs 37 to 40), including whether and how related performance metrics are included in remuneration policies (see paragraph 35);		Governance; * Climate-related factors have not yet been incorporated into the remuneration policy, and the feasibility of incorporating relevant indicators will be subsequently assessed.
19 (b) management’s role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities:		Governance
i) whether the role is delegated to a specific management-level position or management-level committee and how oversight is exercised over that position or committee; and		Governance
ii) whether management uses controls and procedures to support the oversight of climate-related risks and opportunities and, if so, how these controls and procedures are integrated with other internal functions.		Governance

Part D: “Comply or explain” principle Climate-related disclosures		Chapters/Notes
(II) Strategy		
Climate-related risks and opportunities		
20 (a) describe climate-related risks and opportunities that could reasonably be expected to affect the issuer’s cash flows, its access to finance or cost of capital over the short, medium or long term;		Strategy
20 (b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate-related transition risk;		
20 (c) specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons – short, medium or long term – the effects of each climate-related risk and opportunity could reasonably be expected to occur;		
20 (d) explain how the issuer defines ‘short term’, ‘medium term’ and ‘long term’ and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making.		
Business model and value chain		
21 (a) a description of the current and anticipated effects of climate-related risks and opportunities on the issuer’s business model and value chain;		Strategy
21 (b) a description of where in the issuer’s business model and value chain climate-related risks and opportunities are concentrated (for example, geographical areas, facilities and types of assets).		

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Strategy and decision-making	
22(a) information about how the issuer has responded to, and plans to respond to, climate-related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation:	<p>* The Group has identified significant climate-related risks and opportunities. However, as relevant quantitative financial data had not been fully finalized as at the date of the report, only reasonably available information has been disclosed qualitatively in reliance on the reasonable information exemption. Yunkang will continue to refine the disclosure of current and expected financial impacts.</p>
i) current and anticipated changes to the issuer’s business model, including its resource allocation, to address climate-related risks and opportunities;	
ii) current and anticipated adaptation and mitigation efforts (whether direct or indirect);	
iii) any climate-related transition plan the issuer has (including information about key assumptions used in developing its transition plan, and dependencies on which the issuer’s transition plan relies), or an appropriate negative statement where the issuer does not have a climate-related transition plan;	
iv) how the issuer plans to achieve any climate-related targets (including any greenhouse gas emissions targets (if any)), described in accordance with paragraphs 37 to 40; and	
22 (b) information about how the issuer is resourcing, and plans to resource, the activities disclosed in accordance with paragraph 22(a).	
23. An issuer shall disclose information about the progress of plans disclosed in previous reporting periods in accordance with paragraph 22(a).	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Financial position, financial performance and cash flows	
Current financial effect	
24 (a) how climate-related risks and opportunities have affected its financial position, financial performance and cash flows for the reporting period;	<p>* The Group has identified significant climate-related risks and opportunities. However, as relevant quantitative financial data had not been fully finalized as at the date of the report, only reasonably available information has been disclosed qualitatively in reliance on the reasonable information exemption. Yunkang will continue to refine the disclosure of current and expected financial impacts.</p>
24 (b) the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment within the next annual reporting period to the carrying amounts of assets and liabilities reported in the related financial statements.	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Anticipated financial effect	
25 (a) how the issuer expects its financial position to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, taking into consideration:	<p>* The Group has identified significant climate-related risks and opportunities. However, as relevant quantitative financial data had not been fully finalized as at the date of the report, only reasonably available information has been disclosed qualitatively in reliance on the reasonable information exemption. Yunkang will continue to refine the disclosure of current and expected financial impacts.</p>
i) its investment and disposal plans;	
ii) its planned sources of funding to implement its strategy;	
25 (b) how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Climate resilience	
26 (a) the issuer’s assessment of its climate resilience as at the reporting date, which shall enable an understanding of:	<p>Strategy</p> <p>* The Group has disclosed the identified climate-related risks and opportunities, and will further consider the possibility of adopting climate scenario analysis tools to conduct financial impact analysis in the future.</p>
i) the implications, if any, of the issuer’s assessment for its strategy and business model, including how the issuer would need to respond to the effects identified in the climate-related scenario analysis;	
ii) the significant areas of uncertainty considered in the issuer’s assessment of its climate resilience;	
iii) the issuer’s capacity to adjust, or adapt its strategy and business model to climate change over the short, medium or long term;	
26 (b) how and when the climate-related scenario analysis was carried out, including:	
i) information about the inputs used, including:	
(1) which climate-related scenarios the issuer used for the analysis and the sources of such scenarios;	
(2) whether the analysis included a diverse range of climate-related scenarios;	
(3) whether the climate-related scenarios used for the analysis are associated with climate-related transition risks or climate-related physical risks;	
(4) whether the issuer used, among its scenarios, a climate-related scenario aligned with the latest international agreement on climate change;	
(5) why the issuer decided that its chosen climate-related scenarios are relevant to assessing its resilience to climate-related changes, developments or uncertainties;	
(6) time horizons the issuer used in the analysis; and	
(7) what scope of operations the issuer used in the analysis (for example, the operation, locations and business units used in the analysis);	
ii) the key assumptions the issuer made in the analysis;	
iii) the reporting period in which the climate-related scenario analysis was carried out.	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
(III) Risk Management	
27 (a) the processes and related policies an issuer uses to identify, assess, prioritise and monitor climate-related risks, including information about:	Risk management
i) the inputs and parameters the issuer uses (for example, information about data sources and the scope of operations covered in the processes);	Risk management
ii) whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related risks;	
iii) how the issuer assesses the nature, likelihood and magnitude of the effects of those risks (for example, whether the issuer considers qualitative factors, quantitative thresholds or other criteria);	
iv) whether and how the issuer prioritises climate-related risks relative to other types of risks;	
v) how the issuer monitors climate-related risks;	
vi) whether and how the issuer has changed the processes it uses compared with the previous reporting period;	
27 (b) the processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related opportunities);	Risk management
27 (c) the extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer’s overall risk management process.	Risk management

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
(IV) Metrics and Targets	
Greenhouse gas emissions	
28. An issuer shall disclose its absolute gross greenhouse gas emissions generated during the reporting period, expressed as metric tons of CO2 equivalent, classified as:	Metrics and targets
(a) Scope 1 greenhouse gas emissions;	
(b) Scope 2 greenhouse gas emissions; and	
(c) Scope 3 greenhouse gas emissions.	
29 (a) An issuer shall measure its greenhouse gas emissions in accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004) unless required by a jurisdictional authority or another exchange on which the issuer is listed to use a different method for measuring greenhouse gas emissions;	
29 (b) An issuer shall disclose the approach it uses to measure its greenhouse gas emissions including:	
i) the measurement approach, inputs and assumptions the issuer uses to measure its greenhouse gas emissions;	
ii) the reason why the issuer has chosen the measurement approach, inputs and assumptions it uses to measure its greenhouse gas emissions;	
iii) any changes the issuer made to the measurement approach, inputs and assumptions during the reporting period and the reasons for those changes;	
29 (c) for Scope 2 greenhouse gas emissions disclosed in accordance with paragraph 28(b), disclose its location-based Scope 2 greenhouse gas emissions, and provide information about any contractual instruments that are necessary to enable an understanding of the issuer’s Scope 2 greenhouse gas emissions;	
29 (d) for Scope 3 greenhouse gas emissions disclosed in accordance with paragraph 28(c), disclose the categories included within the issuer’s measure of Scope 3 greenhouse gas emissions, in accordance with the Scope 3 categories described in the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011).	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Climate-related risks, opportunities and carbon pricing	
30. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.	<p>* The Group has currently disclosed the qualitative impacts of significant climate-related risks and opportunities. As relevant quantitative financial data had not been fully prepared as at the date of the report, only reasonably available information was used, and qualitative disclosure has been made in reliance on the reasonable information exemption. Yunkang will continue to refine the disclosure of its current and expected financial impacts.</p>
31. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.	
32. An issuer shall disclose the amount and percentage of assets or business activities aligned with climate-related opportunities.	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
<p>33. An issuer shall disclose the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities.</p>	<p>The Group is continuously enhancing its climate-related data collection and management systems. At present, the amounts of capital expenditure, financing, or investment related to climate-related risks and opportunities are still being assessed and are not yet ready for disclosure. The Group will provide the relevant information in due course as progress is made.</p>

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
<p>34 (a) an explanation of whether and how the issuer is applying a carbon price in decision-making (for example, investment decisions, transfer pricing, and scenario analysis);</p> <p>34 (b) the price of each metric tonne of greenhouse gas emissions the issuer uses to assess the costs of its greenhouse gas emissions;</p>	<p>* The Group has not yet adopted an internal carbon pricing mechanism, mainly because the coverage of the domestic carbon market and industry-specific applicable rules are still being improved. The Group will continue to monitor policy developments and industry practices, and assess the feasibility of introducing a carbon pricing mechanism.</p>
<p>Remuneration</p>	
<p>35. An issuer shall disclose whether and how climate-related considerations are factored into remuneration policy, or an appropriate negative statement. This may form part of the disclosure under paragraph 19(a)(iv).</p>	<p>* Climate-related factors have not yet been incorporated into the remuneration policy, and the feasibility of incorporating relevant indicators will be subsequently assessed.</p>
<p>Industry-based metrics</p>	
<p>36. An issuer is encouraged to disclose industry-based metrics that are associated with one or more particular business models, activities or other common features that characterise participation in an industry.</p>	<p>Environmental KPIs</p>

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
Climate-related targets	
37. An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any greenhouse gas emissions targets. For each target, the issuer shall disclose:	<p>* The Group has established qualitative targets for greenhouse gas emissions and disclosed its current action plan. Going forward, it will further assess the feasibility of setting climate-related quantitative targets to continuously enhance climate performance management.</p>
(a) the metric used to set the target;	
(b) the objective of the target (for example, mitigation, adaptation or conformance with science-based initiatives);	
(c) the part of the issuer to which the target applies (for example, whether the target applies to the issuer in its entirety or only a part of the issuer, such as a specific business unit or geographic region);	
(d) the period over which the target applies;	
(e) the base period from which progress is measured;	
(f) milestones or interim targets (if any);	
(g) if the target is quantitative, whether the target is an absolute target or an intensity target;	
(h) how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the target.	
38. An issuer shall disclose information about its approach to setting and reviewing each target, and how it monitors progress against each target, including:	
(a) whether the target and the methodology for setting the target has been validated by a third party;	
(b) the issuer’s processes for reviewing the target;	
(c) the metrics used to monitor progress towards reaching the target;	
(d) any revisions to the target and an explanation for those revisions.	
39. An issuer shall disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer’s performance.	

Part D: “Comply or explain” principle Climate-related disclosures	Chapters/Notes
40. For each greenhouse gas emissions target disclosed in accordance with paragraphs 37 to 39, an issuer shall disclose:	Environmental KPIs
(a) which greenhouse gases are covered by the target;	* The Group has established qualitative targets for greenhouse gas emissions and disclosed its current action plan. Going forward, it will further assess the feasibility of setting climate-related quantitative targets to continuously enhance climate performance management.
(b) whether Scope 1, Scope 2 or Scope 3 greenhouse gas emissions are covered by the target;	
(c) whether the target is a gross greenhouse gas emissions target or a net greenhouse gas emissions target. If the issuer discloses a net greenhouse gas emissions target, the issuer is also required to separately disclose its associated gross greenhouse gas emissions target;	
(d) whether the target was derived using a sectoral decarbonisation approach;	
(e) the issuer’s planned use of carbon credits to offset greenhouse gas emissions to achieve any net greenhouse gas emissions target. In explaining its planned use of carbon credits, the issuer shall disclose:	
(i) the extent to which, and how, achieving any net greenhouse gas emissions target relies on the use of carbon credits;	
(ii) which third-party scheme(s) will verify or certify the carbon credits;	
(iii) the type of carbon credit, including whether the underlying offset will be nature-based or based on technological carbon removals, and whether the underlying offset is achieved through carbon reduction or removal; and	
(iv) any other factors necessary to enable an understanding of the credibility and integrity of the carbon credits the issuer plans to use (for example, assumptions regarding the permanence of the carbon offset).	
Applicability of cross-industry metrics and industry-based metrics	
41. In preparing disclosures to meet the requirements in paragraphs 21 to 26 and 37 to 38, an issuer shall refer to and consider the applicability of cross-industry metrics and industry-based metrics.	Not applicable

FEEDBACK

Dear reader,

Hello! Thank you for reading the Yunkang Group 2025 Environmental, Social and Governance Report. To strengthen communication and exchange with stakeholders and continuously improve the ESG management work of Yunkang Group, we look forward to hearing your valuable feedback.

Yunkang Group Limited
April 2026

1. What is your overall evaluation of this report?
 Good Above average Average No opinion
2. Do you think this report can objectively reflect the actual performance of the Company in fulfilling ESG responsibilities?
 Yes Average No No opinion
3. How would you rate the clarity, accuracy, and completeness of the information, data, and indicators disclosed in this report?
 High Above average Average Below average Low No opinion
4. How do you rate the design and layout of this report?
 Good Above average Average No opinion
5. Which content section of this report interests you the most?
 Maintain leadership in health sector through intelligence-driven innovation Seek long-term success building upon integrity
 Advance progress with partners with excellence in quality and efficiency Pursue sustainable development through low-carbon practices
 Share prosperity for all through people-centric development Care for the community with benevolence
 No opinion
6. Which content section of this report do you think needs the most improvement?
 Maintain leadership in health sector through intelligence-driven innovation Seek long-term success building upon integrity
 Advance progress with partners with excellence in quality and efficiency Pursue sustainable development through low-carbon practices
 Share prosperity for all through people-centric development Care for the community with benevolence
 No opinion
7. What information would you like to know that is not disclosed in this report?
8. What are your opinions and suggestions on the ESG work of the Company and the preparation of this report?
You can send your feedback and suggestions to ir@yunkanghealth.com, and we will fully consider your opinions and suggestions.



云康
YUNKANG